Key Terms Claims 1-3,9-11 FILE 'RECISTRY' ENTERED AT 14:58:57 ON 04 APR 2002 E WATER/CN L1 1 S E3 E SODIUM HYALURONATE/CN 5 L21 S E3 FILE 'CAPLUS' ENTERED AT 15:01:05 ON 04 APR 2002 1 SEA FILE=REGISTRY ABB=ON PLU=ON WATER/CN L11 SEA FILE=REGISTRY ABB=ON PLU=ON "SODIUM HYALURONATE"/CN L2 686 SEA FILE=CAPLUS ABB=ON PLU=ON (L1 OR WATER OR H2O) AND 1.3 (L2 OR (NA OR SODIUM) (W) HYALURONATE) 21 SEA FILE=CAPLUS ABB=ON PLU=ON L3 AND HUMECTANT L4ANSWER 1 OF 21 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:850724 CAPLUS DOCUMENT NUMBER: 135:376535 Composition for make-up or skin-care in a TITLE: powdery form containing a particular binder Hadasch, Anke; Lemann, Patricia; Simonnet, INVENTOR(S): Jean-tierry PATENT ASSIGNEE(S): L'oreal, Fr. Eur. Pat. Appl., 21 pp. SOURCE: CODEN: EPXXDW DOCUMENT TYPE: Patent LANGUAGE: French FAMILY ACC. NUM. COUNT: PATENT INFORMATION: DATE APPLICATION NO. DATE PATENT NO. KIND ______ A2 20011121 EP 2001-401249 20010515 EP 1155676 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO FR 2808999 Α1 20011123 FR 2000-6448 20000519 JP 2002020236 A2 20020123 JP 2001-148415 20010517 CN 1331967 20020123 CN 2001-122173 20010518 Α FR 2000-6448 A 20000519 PRIORITY APPLN. INFO.: MARPAT 135:376535 OTHER SOURCE(S): A make-up compn. contains a powdery phase and a binding phase which a continuous aq. phase. A binding phase contained iso-Pr myristate 1.64, castor oil 2.46, vaseline oil 12.36, liq. lanolin 1.26, water 70.95, imidazolinyl urea 0.3, glycerin 5, Acylglutamate HS-11 0.03, phytantriol 2.97, vaseline 2.28, chlorphenesine 0.25, and polyoxyethylene sorbitan monopalmitate 0.5%. A cosmetic make-up contained talc 77.06, iron oxide 2.74, Nylon powder 10, titanium oxide 1, preservative 0.2, and above binding phase 9%. TΤ 9067-32-7, Sodium hyaluronate RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (compn. for make-up or skin-care in powdery form contg. particular binder)

Searcher: Shears 308-4994

2001:472455 CAPLUS

ANSWER 2 OF 21 CAPLUS COPYRIGHT 2002 ACS

135:66057

L4

ACCESSION NUMBER: DOCUMENT NUMBER:

10/038830 Skin compositions containing polyoxyethylene TITLE: dicarboxylic acid esters Ohmori, Takashi; Miyahara, Reiji; Kakoki, INVENTOR(S): Hiroyuki; Namba, Tomiyuki PATENT ASSIGNEE(S): Shiseido Company, Ltd., Japan PCT Int. Appl., 49 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: Japanese FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE _____ ---------WO 2000-JP8982 WO 2001045665 A1 20010628 20001219 W: KR, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR A2 JP 2000-17423 20000126 JP 2001240526 20010904 A2 JP 2000-238126 20000807 JP 2002053451 20020219 EP 1153602 A1 20011114 EP 2000-981822 20001219

PT, IE, FI PRIORITY APPLN. INFO.: JP 1999-360818 A 19991220 JP 2000-17423 A 20000126 JP 2000-238126 A 20000807

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,

W 20001219

WO 2000-JP8982 Disclosed are skin compns. for external use which contain AΒ polyoxyethylene dicarboxylic acid esters R10[(Me)CHCH20] \times (C2H50)mCOR3CO(OC2H5)n[O(Me)CHCH2]yOR2 (R1, R2 = H, C1-4 (blanched) alkyl; m, n, x, y = 0-5, provided m, n, x and y do not represent 0 at the same time; and R3 = branched or linear C0-10 alkylene). Because of contg. the polyoxyethylene dicarboxylic acid

esters and a humectant, these compns. are excellent in the texture, in particular, smoothness in using and free from stickiness and exert a prolonged-moistening effect. A cosmetic lotion contg. ethanol 10, glycerin 5, 1,3-butylene glycol 5, diethoxyethyl succinate 0.001, nicotinamide 0.3, sodium pyrrolidone carboxylate 0.5, and water q.s. to 100 % was formulated.

IT 9067-32-7, Sodium hyaluronate

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(skin compns. contg. polyoxyethylene dicarboxylic acid esters and moisturizers)

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 3 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

PATENT ASSIGNEE(S):

2000:817459 CAPLUS

DOCUMENT NUMBER: TITLE:

133:366433

INVENTOR(S):

Antimicrobial compositions for skin disease

Noguchi, Yasuhisa; Tanaka, Yukihisa Nippon Oil and Fats Co., Ltd., Japan

SOURCE:

Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

KIND DATE APPLICATION NO. DATE PATENT NO. ______ _____ A2 20001121 JP 2000-1986 20000107 JP 2000319171 JP 1999-55359 A 19990303 PRIORITY APPLN. INFO.: The antimicrobial compns. comprise bactericidal and disinfecting agents 0.01-20, humectants 0.001-20 and sebum-like substances 0.05-20 wt.%. The compn. may also contain substances such as dexamethasone and prednisolone. An ointment contained benzalkonium chloride 0.01, sodium hyaluronate 0.001, squalene 0.1 and ointment base to 100 wt.%. The ointment base contained e.g. petrolatum 25, stearyl alc. 20, propylene glycol 12, ethoxykated hardened castor oil 4, glycerol monostearate 1, Me p-hydroxybenzoate 0.1 Pr p-hydroxybenzoate 0.1 and purified water to 100 wt.%. The prepns. are effective in treating . atopic dermatitis and other skin diseases.

L4 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: DOCUMENT NUMBER:

2000:513464 CAPLUS 133:109653

TITLE:

Active oxygen-free cosmetic compositions

INVENTOR(S): Nishioka, Hajime

PATENT ASSIGNEE(S):

Faith Co., Ltd., Japan; Kojima, Tsuyoshi

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
APPLICATION NO. DATE
    PATENT NO.
                    KIND DATE
                    A1 20000727 WO 1999-JP6851 19991206
                    ----
    WO 2000042976
           AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
            CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
            ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
            LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
            SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
            YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                    JP 1999-297842 19991020
    JP 2000273034
                    A2 20001003
                         20020123
                                        EP 1999-973627
                                                         19991206
    EP 1174108
                     A1
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
            PT, IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.:
                                      JP 1999-12115
                                                     A 19990120
                                      JP 1999-297842
                                                     A 19991020
                                      WO 1999-JP6851
                                                    W 19991206
    Disclosed are cosmetics generating no active oxygen. These
```

AB Disclosed are cosmetics generating no active oxygen. These cosmetics are prepd. by combining components (bases, antioxidants, humectants, neutralizing agents, thickeners, foaming agents, preservatives, refreshing agents, buffers, pH regulating agents, coloring matters, fillers, sapong. agents, dispersants, anti-inflammatory agents, emulsifiers, fats and oils, UV light absorbers, skin-conditioners, solubilizers, surfactants,

astringents, moisturizers, emollients, UV light scattering agents or thickening aids) with one or more substances generating no active oxygen. A cosmetic lotion contg. conc. glycerin 8, diglycerin 4, modified alc. 5, dipottasium glycyrrhizinate 0.1, sodium hyaluronate 0.02, placenta ext. 0.3, Saxifragaceae ext. 0.2, chamomile ext. 0.5, garlic ext. 0.5, and water q.s. to 100% was prepd.

IT 9067-32-7, Sodium hyaluronate

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(active oxygen-free cosmetic compns. contg.)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR

THIS RECORD. ALL CITATIONS AVAILABLE IN

THE RE FORMAT

L4 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:470370 CAPLUS

DOCUMENT NUMBER: 133:79051

TITLE: Composition for prevention of striae gravidarum

INVENTOR(S):
Takashima, Yoshie

PATENT ASSIGNEE(S): Kansai Koso K. K., Japan SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

humectants, skin softening agents and cell activators at ratio of 0.001-5: 0.01-50: 0.001-5. A cream contained sodium hyaluronate 0.1, avocado oil 3, squalane 3, octyl dodecanol 2, natural vitamin E 1, ginseng ext. 1, Scutellaria baicalensis ext. 1, yeast ext. 1, glycerol tri-2-ethylhexanoate 12, stearic acid 3, POE sorbitan monostearate 4, cetanol 5, glycerin 5 sodium hydroxide 0.7 and purified water to 100 parts.

IT 9067-32-7, Sodium hyaluronate
 RL: BUU (Biological use, unclassified); BIOL (Biological study);
 USES (Uses)

(compn. for prevention of striae gravidarum)

L4 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:374462 CAPLUS

DOCUMENT NUMBER: 133:155123

TITLE: Differential scanning calorimetry studies on the

mechanism of skin-softening effect of sodium

acetylhyaluronate

AUTHOR(S): Oka, T.; Ueno, N.; Yanaki, T.

CORPORATE SOURCE: New Technology Research Laboratories, Basic

Research Center, Shiseido Co. Ltd., Yokohama,

223-8553, Japan

SOURCE: Polymer (2000), 41(16), 6055-6059

CODEN: POLMAG; ISSN: 0032-3861

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A novel humectant, sodium acetylhyaluronate (AcHA), was found to have an excellent skin-softening effect on the stratum corneum. To clarify the mechanism of the skin-softening effect, the hydration behavior of AcHA was investigated by DSC. The results suggested that the amt. of adsorbed water of AcHA in powder form was equal to that of HA. However, the DSC results showed that the bound water content in the stratum corneum treated with AcHA was markedly greater than that of HA-treated stratum corneum. Apparently, AcHA could enhance the intrinsic water holding capacity of stratum corneum. Thus, the excellent skin-softening effect of AcHA is due to the enhancement of the bound water content in the stratum corneum.

REFERENCE COUNT:

31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1999:425544 CAPLUS

ACCESSION NUMBER: DOCUMENT NUMBER:

131:63449

TITLE:

Skin protection preparation containing activated

aluminum chlorohydrate

INVENTOR(S):

Birrenbach, Gerd; Gabard, Bernard

PATENT ASSIGNEE(S):

Spirig A.-G. Pharmazeutische Praeparate, Switz.

SOURCE:

Eur. Pat. Appl., 11 pp. CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

Skin prepns. contg. activated Al chlorohydrate [Al2(OH)(6-x)Clx]n (0 < x < 6) and/or Al Zr chlorohydrate 0.5-30, humectant 0.5-20, and lipid or fatty acid ester 1.0-80 wt.%, along with conventional additives, are effective in preventing skin damage (e.g. eczema or irritation) from toxic substances. Thus, an aq. phase contg. distd. water 62.9, glycerin 5.0, Al chlorohydrate 5.0, and hexamidine isethionate (preservative) 0.1 was combined at 80.degree. with a lipid phase contg. paraffin oil 8.0, octyl palmitate 4.0, jojoba oil 4.0, behenyl alc. 7.5, ceteth-10 1.5, steareth-20 1.5 parts at 80.degree., the melt was homogenized, cooled to room temp., and 0.5 part phenoxyethanol (preservative) was added to provide a homogeneous oil-in-water cream emulsion.

IT 9067-32-7, Sodium hyaluronate

RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(humectant; skin protection prepn. contg. activated aluminum chlorohydrate)

4

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN

THE RE FORMAT

ANSWER 8 OF 21 CAPLUS COPYRIGHT 2002 ACS 1997:699495 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 127:350990

Development and application of acetylhyaluronate TITLE:

for cosmetics, a novel humectant

having an excellent skin-softening effect for

stratum corneum

AUTHOR(S): Oka, Takashi; Yanaki, Toshio

Basic Res. Lab., Shiseido Res. Cent., Yokohama, CORPORATE SOURCE:

223, Japan

Fragrance J. (1997), 25(10), 9-15 SOURCE:

CODEN: FUJAD7; ISSN: 0288-9803

PUBLISHER: DOCUMENT TYPE: Fureguransu Janaru Sha Journal; General Review

LANGUAGE: Japanese

A review with 18 refs. To endow sodium

hyaluronate (HA) with precious functions, we synthesized sodium acetylhyaluronate (AcHA), which was found to have a superb moisturizing effect and has an excellent skin-softening effect. clarify mechanism of the effect, the hydration and adsorption of AcHA for the stratum corneum were measured. The results indicated that AcHA increased the water content in stratum corneum and could be efficiently adsorbed on the stratum corneum. Consequently, AcHA reduced transepidermal water loss (TEWL) and sufficiently softened the stratum corneum. of AcHA in a cosmetic formula, it was also obsd. that 0.2% AcHA-lotion could increase the water contents in stratum corneum, reduce the TEWL, and improve scaly dry skin condition.

9067-32-7D, acetyl derivs.

RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(skin-softening effect of acetylhyaluronate on stratum corneum and its application to cosmetics)

ANSWER 9 OF 21 CAPLUS COPYRIGHT 2002 ACS

1997:548112 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 127:210182

Development and application of acetylhyaluronate TITLE:

for cosmetics

AUTHOR(S): Oka, Takashi; Uemura, Masaaki; Ueno, Norio;

Yanaki, Toshio; Yamaguchi, Michihiro

Shiseido Res. Cent., Kanagawa, 223, Japan CORPORATE SOURCE:

Sci. Conf. Asian Soc. Cosmet. Sci., 3rd (1997), SOURCE:

234-245. Asian Societies of Cosmetic

Scientists: Taichung, Taiwan.

CODEN: 64XSAZ

DOCUMENT TYPE: Conference LANGUAGE: English

To maintain healthy and fresh skin, it is necessary to moisten sufficiently stratum corneum. Due to aging, surroundings, phys. constitution, and other factors, the stratum corneum always has a tendency to lose its normal water content. It is

effective to apply humectants to the skin for keeping the

normal water content. In general, humectants, sodium hyaluronate (HA), which is made from safe

> Searcher : 308-4994 Shears

biol. sources and is hardly subject to relative humidity of environment, has a very high moisturizing effect. To endow HA with precious functions, the authors synthesized varieties of HA derivs. and evaluated their usefulness for cosmetic products. After numerous investigations for finding HA derivs., the authors eventually discovered a novel HA deriv., sodium acetylhyaluronate (AcHA), which increases moisturizing effect and has a very high skin-softening effect for stratum corneum. To clarify the mechanism of the skin-softening effect, the hygroscopicity of AcHA was The hygroscopicity of AcHA was equal to that of HA. However, DSC also showed that the bound water content of stratum corneum treated with AcHA was markedly greater than that of HA-treated stratum corneum. It was also found by in an vivo test that AcHA raised the water content of stratum corneum more than HA did. Apparently, AcHA could enhance the intrinsic water-holding capacity of the stratum corneum. Thus, there was an interaction between AcHA and stratum corneum and this could induce the strong skin-softening effect. To investigate this interaction, the adsorption of AcHA on human skin was measured. amt. of adsorption of AcHA was markedly greater than that of HA. This was consistent with the fact that AcHA is an amphiphilic polymer having an effect of lowering the surface tension. Considering these results and properties, it was suggested that AcHA could be adsorbed efficiently on human skin, and this adsorption reduced the transepidermal water loss and resulted in the skin-softening effect. Upon the use of AcHA in cosmetic formulation, it as obsd. that a lotion contg. 0.2% AcHA could increase the water contents in stratum corneum, reduce the transepidermal water loss, and improve the skin condition. Although further research is necessary to demonstrate the skin-softening effect of AcHA, the superior effect of AcHA as a humectant was confirmed in this study.

IT 9067-32-7DP, Sodium hyaluronate, acetyl
derivs.

RL: BUU (Biological use, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(acetylhyaluronate for cosmetics)

IT 9067-32-7, Sodium hyaluronate

RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL
(Biological study); USES (Uses)
 (acetylhyaluronate for cosmetics)

L4 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:399963 CAPLUS

DOCUMENT NUMBER: 127:23497

-TITLE: - - - - - - - Skin care composition comprising sunscreen,

humectant and exfolliant

INVENTOR(S): Campbell, Sean; Edsor, Marion; Herd, John

PATENT ASSIGNEE(S): Fernsoft, UK
SOURCE: Brit. UK Pat. Appl., 24 pp.

CODEN: BAXXDU

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

.

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```
GB 2304573
                    A1 19970326
                                         GB 1995-17711
                                                         19950831
                     B2 19990728
    GB 2304573
    Cosmetic skin care compn. comprising a sunscreen e.g. octylmethoxy
AB
    cinnamate, emollient e.g. glyceryl stearate, humectant
    e.g. glycerin, anti-oxidant e.g. vitamins A/C/E, exfolliant e.g.
     .alpha.-hydroxy acids from fruit ext., bodifier e.g. cetyl alc.,
    emulsifier e.g. sorbitan stearate, preservative e.g. Pr paraben,
    sequestering agent e.g. disodium EDTA, delivery agent, e.g.
    phytantriol and water. Vitamins A and C may be liposomal
    form. Formulations of different cosmetics are claimed.
    9067-32-7, SODIUM HYALURONATE
IT
    RL: BUU (Biological use, unclassified); BIOL (Biological study);
    USES (Uses)
        (skin care compn. comprising sunscreen, humectant and
       exfolliant)
    ANSWER 11 OF 21 CAPLUS COPYRIGHT 2002 ACS
                        1996:732503 CAPLUS
ACCESSION NUMBER:
DOCUMENT NUMBER:
                        126:36867
TITLE:
                        Humectant compositions and their use
                        in manufacturing cosmetics or topical
                        preparations
                        Ooyama, Keiichi; Fujisawa, Masaaki; Kobayashi,
INVENTOR(S):
                        Rie; Fujimoto, Naoko; Tsuji, Misako
PATENT ASSIGNEE(S):
                        Nisshin Oil Mills Ltd, Japan
SOURCE:
                        Jpn. Kokai Tokkyo Koho, 15 pp.
                        CODEN: JKXXAF
DOCUMENT TYPE:
                        Patent
                        Japanese
LANGUAGE:
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:
    PATENT NO.
                 KIND DATE
                                        APPLICATION NO.
                                                         DATE
                     ____
                                         _____
     -----
    JP 08259433
                    A2 19961008
                                         JP 1995-88666
                                                          19950323
    JP 3159622
                     B2
                           20010423
                                         WO 1996-JP2739
                                                          19960924
    WO 9813436
                     A1 19980402
        RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
            PT, SE
                                       JP 1995-88666 A 19950323
PRIORITY APPLN. INFO.:
    Humectant compns. contg. water-sol. polyvalent
    alcs. (glycerol and/or sorbitol), lecithin, 3-methyl-1,3-butylene
    glycol and water, and their use in manufg. cosmetics or
    topical prepns. are claimed. A lotion contained glycerin 5,
    diglycerin 5, hydrogenated eggyolk lecithin 2, 3-methyl-1,3-butylene
    glycol 10, neopentyl glycol dicaprate 1, Et p-hydroxybenzoate 0.1,
    sodium hyaluronate 0.1 and water to 100
    wt.%.
IΤ
    7732-18-5, Water, biological studies
    RL: BUU (Biological use, unclassified); BIOL (Biological study);
    USES (Uses)
        (humectant compns. and their use in manufg. cosmetics
       or topical prepns.)
    ANSWER 12 OF 21 CAPLUS COPYRIGHT 2002 ACS
T.4
ACCESSION NUMBER:
                        1995:574021 CAPLUS
```

DOCUMENT NUMBER: 122:298724

TITLE: Cosmetic makeup compositions

INVENTOR(S): Igo-Kemenes, Kataline; Boxshall, Alison Ruth;

Morris, Sian

PATENT ASSIGNEE(S): Procter and Gamble Co., USA

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

يكل

| PA | TENT 1 | NO. | | KI | ND . | DATE | | | A | PPLI | CATI | ON N | э. | DATE | | |
|---------|--------|------|------|-----|------|------|------|-----|------|-------|------|------|-----|-------|------|-----|
| WO | 9509 | 598 | | A. | 1 | 1995 | 0413 | | W | 0 19 | 94-U | S111 | 38 | 1994 | 0930 | |
| | W: | AM, | ΑU, | BB, | BG, | BR, | BY, | CA, | CN, | CZ, | EE, | FI, | GE, | ΗU, | JP, | KG, |
| | | ΚP, | KR, | ΚZ, | LK, | LR, | LT, | LV, | MD, | MG, | MN, | NO, | ΝZ, | PL, | RO, | RU, |
| | | SI, | SK, | ТJ, | TT, | UA, | US, | UZ, | VN | | | | | | | |
| | RW: | KE, | MW, | SD, | SZ, | BF, | ВJ, | CF, | CG, | CI, | CM, | GΑ, | GN, | ML, | MR, | ΝĒ, |
| | | SN, | TD, | TG | | | | | | | | • | | | | |
| CA | 2173 | 112 | | A | Ą | 1995 | 0413 | | C. | A 19 | 94-2 | 1731 | 12 | 1994 | 0930 | |
| AU | 9480 | 124 | | A: | 1 | 1995 | 0501 | | A | U 19 | 94-8 | 0124 | | 1994 | 0930 | |
| AU | 6912 | 05 | | B | 2 | 1998 | 0514 | | | | | | | | | |
| CN | 1134 | 661 | | Α | | 1996 | 1030 | | C | N 19 | 94-1 | 9409 | 4 | 1994 | 0930 | |
| JP | 0950 | 4009 | | T | 2 | 1997 | 0422 | | J | P 19 | 94-5 | 1093 | 0 | 19940 | 0930 | |
| US | 6001 | 373 | | Α | | 1999 | 1214 | | U. | S 19 | 96-6 | 1968 | 4 | 19960 | 0402 | |
| PRIORIT | Y APP | LN. | INFO | . : | | | | 1 | GB 1 | 993- | 2034 | 9 | | 1993 | 1002 | |
| | | | | | | | | | EP 1 | 993- | 3080 | 92 | | 1993 | 1008 | |
| | | | | | | | | 1 | WO 1 | 994-1 | US11 | 138 | | 19940 | 0930 | |

AB A makeup compn. in the form of a water-in-oil or oil-in-water emulsion comprises silicone oil selected from volatile silicones, nonvolatile silicones and mixts. thereof, optionally humectant, at least one coated or uncoated iron oxide-type pigment and a TiO2-coated platelet-type interference pigment material having a TiO2 layer thickness of 120-160 nm or a whole no. multiple thereof. The makeup compn. exhibits improved moisturization, together with improved skin feel and appearance and color correction benefits.

IT 9067-32-7, Sodium hyaluronate

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(cosmetic makeup compns. contg. silicone oils and pigments and emollients)

L4 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:541751 CAPLUS

DOCUMENT NUMBER: 121:141751

TITLE: Pharmaceutical compositions containing

hyaluronic acid and urea for treatment of

epithelial diseases Gallina, Damian J.

INVENTOR(S): Gallina, Damian J.

PATENT ASSIGNEE(S): Patent Biopharmaceutics Inc., USA

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

, it

```
DATE
    PATENT NO.
                     KIND DATE
                                          APPLICATION NO.
                     ----
     _____
                                          -----
                                          WO 1993-US12369 19931223
                     A1
                           19940721
        W: AU, CA, FI, HU, JP, KR, NO
        RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT,
                           19960827
                                          US 1993-101826
                                                          19930804
    US 5550112
                      Α
                                          AU 1994-58524
    AU 9458524
                      A1
                           19940815
                                                          19931223
                           19951018
                                         EP 1994-904499
                                                          19931223
    EP 676963
                      A1
        R: BE, CH, DE, ES, FR, GB, IT, LI, NL
    JP 08505388
                      T2 19960611
                                          JP 1993-516025
                                                          19931223
PRIORITY APPLN. INFO.:
                                       US 1992-996938
                                                          19921230
                                       US 1993-101826
                                                          19930804
                                       US 1992-966938
                                                          19921230
                                                          19931223
                                       WO 1993-US12369
    Pharmaceutical compns. contg. a pharmaceutically acceptable carrier,
AB
    urea, and hyaluronic acid or a pharmaceutically salt thereof are
    used for treatment of cutis, anorectal epithelium and rectal mucosa.
    A cream contained urea 0.10, Na hyaluronate 15,
    Fattibase 4.5, glycerin 1.5, lecithin 1.5, PEG-400 1.5, and
    water 75.90 g. The cream was successfully used for
    treatment of patients with contact dermatitis.
ΙT
    9067-32-7, Sodium hyaluronate
    RL: BIOL (Biological study)
        (pharmaceutical compns. contg. urea and, for treatment of
       epithelial diseases)
    ANSWER 14 OF 21 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER:
                        1992:557674 CAPLUS
DOCUMENT NUMBER:
                        117:157674
                        Isotonic eyedrops having nonnewtonian
TITLE:
                        rheological properties
INVENTOR(S):
                        Dikstein, Shabtay
PATENT ASSIGNEE(S):
                        Israel
SOURCE:
                        U.S., 8 pp. Cont.-in-part of U.S. Ser. No.
                        350,286, abandoned.
                        CODEN: USXXAM
DOCUMENT TYPE:
                        Patent
                        English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
    PATENT NO.
                     KIND DATE
                                         APPLICATION NO.
                                                          DATE
                          -----
                                          ______
                                          US 1990-620102
                                                          19901130
    US 5106615
                     Α
                           19920421
                                      IL 1986-80298
                                                          -19861014
    IL 80298 - A1 -19930131
                                       IL 1986-80298
PRIORITY APPLN. INFO.:
                                                          19861014
                                       US 1987-107575
                                                          19871013
                                       US 1989-350286
                                                          19890511
AB
    The title eyedrops contain (1) an anionic polymer having mol. wt.
    500,000 - 4,000,000 at a concn. resulting in a viscosity of
     .ltoreq.150 cP at 1 s-1 shear rate, which decreases to .ltoreq.30 cP
    s-1 at 100 s-1 shear rate, and (2) a humectant
```

Searcher: Shears 308-4994

moisturizing polyol of mol. wt. .ltoreq.500, having strong water-holding properties, at isotonic or slightly above or below isotonic concn. which soln. contains .ltoreq.1.5 mmol. of monovalent or bivalent salts, not including the salts of the anionic

polymer. An isotonic ophthalmic soln. contained glycerol 2.75, Na hyaluronate 0.10, idoxuridine 0.1 g, and water 100mL.

IT 9067-32-7, Sodium hyaluronate

RL: BIOL (Biological study)

(isotonic ophthalmic solns. contg. polyols and)

L4 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1991:214190 CAPLUS

DOCUMENT NUMBER: 114:214190

DOCUMENT NOMBER: 114.214190

TITLE: Solid highly soluble cosmetic composition

INVENTOR(S):
Funatsu, Shinichiro

PATENT ASSIGNEE(S): Shiseido Co., Ltd., Japan SOURCE: Eur. Pat. Appl., 5 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | | APPLICATION NO. | DATE |
|----------------------|--------|----------|----|-----------------|----------|
| | | | | | |
| EP 412449 | A2 | 19910213 | | EP 1990-114944 | 19900803 |
| EP 412449 | А3 | 19921125 | | | |
| EP 412449 | B1 | 19960110 | | | |
| R: DE, ES, | FR, GB | , IT, NL | | | |
| JP 03068507 | A2 | 19910325 | | JP 1989-204488 | 19890807 |
| JP 2865320 | B2 | 19990308 | | | |
| CA 2022478 | ÀА | 19910208 | | CA 1990-2022478 | 19900801 |
| ES 2081324 | т3 | 19960301 | | ES 1990-114944 | 19900803 |
| AU 9060175 | A1 | 19910207 | | AU 1990-60175 | 19900806 |
| AU 631233 | B2 | 19921119 | | | |
| PRIORITY APPLN. INFO | .: | | JP | 1989-204488 | 19890807 |

AB A solid cosmetic comprises a freeze-dried product of an aq. soln. contg. a water-sol. solid substance and a water -sol. polymer as a thickener or a humectant. Thus, mannitol 2.0, PEG-4000 6.0, sucrose 2.0, pectin 0.2, algae colloid 0.2, Na hyaluronate 0.5, Na PCA 0.5, atelocollagen (2% aq. soln.) 1.0, placenta ext. 0.5, and deionized water 87.1 % were mixed and freeze-dried to give a cosmetic powder.

L4 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1990:11793 CAPLUS

DOCUMENT NUMBER:

112:11793

TITLE:

Skin preparations containing ceramides,

glucosylceramides, and/or galactosylceramides

and low molecular-weight acidic

mucopolysaccharides for prevention of aging

INVENTOR(S):

Miyamoto, Tatsu; Uchida, Ryoichi

PATENT ASSIGNEE(S):

Kanebo, Ltd., Japan

SOURCE:

Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ---------_____ _____ A2 19870715 19890125 JP 1987-176904 JP 01022809 JP 06104620 B4 19941221

AB Skin prepns. contain ceramides, glucosylceramides, and/or galactosylceramides and low mol.-wt. acidic mucopolysaccharides and/or their salts. The skin prepns. show rough skin-treatment, corneum-treatment, and moisturizing effects and prevent aging of The skin prepns. require no addn. of large amt. of other humectant agents, e.g. glycerin, propylene glycol, etc., which absorb water in corneum, and softeners, e.g. liq. paraffin, vaseline, etc., which inhibit normal metab. in skin. A two-layer skin lotion contg. olive oil 15.0, iso-Pr myristate 5.0, polyoxyethylene nonylphenyl ether 0.5, propylene glycol 3.0, glycerin 5.0, methylparaben 0.1, EtOH 7.0, ceramides 0.4, hyaluronic acid (I) 0.5 wt.%, and purified water balance, was applied to legs of 20 middle-aged subjects suffering from rough skin, dry skin, or senile dry skin; a decrease of perspiration (TWL value) as an index of moisturizing effect was obsd. in 15 subjects, vs. 8 for a control treated with a lotion free of I.

IT 9067-32-7, Sodium hyaluronate

RL: BIOL (Biological study)

(cosmetics contg. (glucosyl or galactosyl) ceramides and, for aging prevention)

L4 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1989:540222 CAPLUS

DOCUMENT NUMBER:

111:140222

TITLE:

Skin cosmetics containing oil-in-water

dispersions containing natural surfactants and

liposome-water dispersions

INVENTOR(S):

Takenouchi, Masanori; Hirai, Yoshikazu Pola Chemical Industries, Inc., Japan

PATENT ASSIGNEE(S): SOURCE:

Fr. Demande, 22 pp.

CODEN: FRXXBL

DOCUMENT TYPE:

Patent

LANGUAGE:

French

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

| PATENT NO. | KIND DATE | | APPLICATION NO. | DATE | |
|-----------------------|-----------|----------|-----------------|----------|--|
| | | | | | |
| FR 2614787 | A1 | 19881110 | FR 1988-6182 | 19880506 | |
| FR 2614787 | в1 | 19940603 | | | |
| JP 63275506 | A2 | 19881114 | JP 1987-109832 | 19870507 | |
| JP 2554880 | B2 | 19961120 | | | |
| PRIORITY APPLN. INFO. | : | | JP 1987-109832 | 19870507 | |

AB Skin cosmetics comprise an oil-in-water dispersion contg.
natural substances having surfactant and humectant
properties and a liposome-water dispersion contg. an
intercellular lipid; the ingredients are mixed in such a manner that
the two dispersions coexist in the mixt. The surfactants are
selected from collagen or casein or their hydrolyzates, fibroin or
glycyrrhizin or their derivs.; the humectants are selected
from hyaluronic acid, chondroitin sulfate, dermatan sulfate, or
their salts, chitin, chitosan, or their derivs., collagen or its
hydrolyzates, gelatin, glycerol, polyglycerol, and carboxyvinyl
polymers; the intercellular lipids are selected from phospholipids,

glycolipids, and cholesterol or its derivs. The cosmetics can contain synthetic surfactants in addn. to the natural surfactants thus named. An emollient cream contained spermaceti 3.0, beeswax 2.0, liq. paraffin 15.0, behenyl alc. 5.0, preservatives 0.3, elastin hydrolyzate 2.0, 1,3-butylene glycol 10.0, carboxymethylchitin 0.5, H2O 53.2, soy lecithin 2.0, sphingoglycolipids 1.0, phytosterol 0.5, glycerol 5.0, and vitamin A 0.5 parts by wt. The cream was prepd. by mixing an oily phase contg. spermaceti, bees wax, liq. paraffin, behenyl alc., and preservatives with an aq. phase contg. elastin hydrolyzate, 1,3-butylene glycol, carboxymethylchitin, and H2O to form a water-in-oil dispersion to which an aq. liposome dispersion was added; the liposomes consisted of soy lecithin, sphingoglycolipids, phytosterol, glycerol, and vitamin A. The moisturizing effect of this cosmetic is prolonged by 10 h, compared the a similar cosmetic contg. addnl. 2.0% by wt. glycerol monostearate and 3.0% by wt. ethoxylated cetyl alc. (i.e. synthetic surfactant) instead of elastin hydrolyzates.

IT 9067-32-7, Sodium hyaluronate

RL: BIOL (Biological study)

(oil-in-water dispersions contg., cosmetics from aq.

liposome dispersions and)

L4 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:
DOCUMENT NUMBER:

1989:179564 CAPLUS

TITLE:

Preparation of aminopolysaccharide derivatives,

especially chitosonium salts, by acid

decrystallization, and their medical, cosmetic,

and liquid separation uses

INVENTOR(S):

Partain, Emmett Malone, III; Brode, George

Lewis, II

110:179564

PATENT ASSIGNEE(S):

Union Carbide Corp., USA PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LÁNGUAGE:

SOURCE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

| PA | TENT | NO. | | KIN | 1D | DATE | | | | APPLICATI | ON NO. | DATE |
|---------|-------|---------|-------|--------|----------|------|------|-----|----|-----------|--------|----------|
| WO. | 8707 | 618 | | A1 | L | 1987 | 1217 | •• | | WO 1987-U | JS1246 | 19870602 |
| | W: | | | | | | | | | | | |
| | RW: | ΑT, | BE, | CH, | DE, | FR, | GB, | ΙΤ, | LU | , NL, SE | | |
| EP | 2715 | 51 | | A1 | L | 1988 | 0622 | | | EP 1987-9 | 04163 | 19870602 |
| - EP | 2715 | 51 - | • | - B1 | <u>t</u> | 1996 | 1030 | | | - | | |
| | R: | AT, | BE, | CH, | DE, | FR, | GB, | IT, | LI | , LU, NL, | SE | |
| JP | 6350 | 3466 | | T2 | 2 | 1988 | 1215 | | | JP 1987-5 | 03854 | 19870602 |
| JP | 0707 | 6241 | | В4 | 1 | 1995 | 0816 | | | | | |
| AT | 1447 | 81 | | E | | 1996 | 1115 | | | AT 1987-9 | 904163 | 19870602 |
| CA | 1283 | 655 | | A1 | L | 1991 | 0430 | | | CA 1987-5 | 39050 | 19870608 |
| US | 4929 | 722 | | Α | | 1990 | 0529 | | | US 1988-1 | L89312 | 19880203 |
| PRIORIT | Y APP | LN. | INFO. | . : | | | | | US | 1986-8713 | 381 | 19860606 |
| | | | | | • | | | 1 | OW | 1987-US12 | 246 | 19870602 |
| | | | | | | | | _ | | _ | | |

AB The heterogeneous acid decrystn. of aminopolysaccharides, esp. chitosan, using diluent, org. acid, and H2O, provides novel salts and covalent derivs. while avoiding processing

difficulties encountered with aq. processing. The products are useful in fluid sepn., personal care products, and biomedical applications. Chitosan (80% deacetylated) was ground and slurried in H2O-Me2CO, and itaconic acid was added as a powder and the slurry was stirred for 3 h. The slurry was allowed to settle, supernatant was decanted, Me2CO was added, and the polymer was collected by filtration; the mass gain of chitosonium itaconate was 0.30. Chitosonium itaconate was dissolved in hot H2O, the soln. cooled, sulfanilamide was added, and a film was cast and cured at 100.degree. for 18 h. Although the film was insol. in water, >95% of the sulfanilamide was extd. from the film in H2O after 30 min.

IT 9067-32-7, Sodium hyaluronate

RL: BIOL (Biological study)

(blend with chitosan pyrrolidonecarboxylate, for wound dressings)

L4 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1989:121403 CAPLUS

DOCUMENT NUMBER:

110:121403

TITLE:

Isotonic humectant eye drops

INVENTOR(S):

Dikstein, Shabtay

PATENT ASSIGNEE(S):

Resdevco Research and Development Co., Ltd.,

Israel

SOURCE:

Brit. UK Pat. Appl., 3 pp.

CODEN: BAXXDU

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--------------|----------|-----------------|----------|
| | | - | | | |
| | GB 2196255 | A1 | 19880427 | GB 1987-24112 | 19871014 |
| | GB 2196255 | В2 | 19910515 | | |
| | IL 80298 | A1 | 19930131 | IL 1986-80298 | 19861014 |
| | SE 8703972 · | A | 19880415 | SE 1987-3972 | 19871013 |
| | SE 503469 | C2 | 19960624 | | |
| | CA 1311418 | A1 | 19921215 | CA 1987-549162 | 19871013 |
| | FR 2604906 | A1 | 19880415 | FR 1987-14176 | 19871014 |
| | FR 2604906 | B1 | 19920207 | | |
| | DE 3734835 | A1 | 19880601 | DE 1987-3734835 | 19871014 |
| | DE 3734835 | C2 | 19970717 | | |
| 10 | RITY APPLN. I | NFO.: | | IL 1986-80298 | 19861014 |

AB Isotonic eye drops contain an org. humectant and the required adjuvants. These solns. contain <1.5 mmol/L salts. An isotonic ophthalmic soln. contained 2.75 g glycerol, 0.05 g

Na hyaluronate, and 100 mL H2O.

Dexamethasone di-Na phosphate $(0.05\ g)$ was added to this base to give an antiinflammatory pharmaceutical which did not irritate the eyes.

L4 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1985:546968 CAPLUS

DOCUMENT NUMBER:

103:146968

TITLE:

Humectants and their effects on the

moisturization of skin

AUTHOR(S):

Ozawa, Tatsuya; Nisiyama, Shoji; Horii, Izumi; Kawasaki, Kiyoshi; Kumano, Yoshimaru; Nakayama,

Yasuhisa

CORPORATE SOURCE: Shiseido Lab., Yokohama, Japan SOURCE: Hifu (1985), 27(2), 276-88

CODEN: HIFUAG

DOCUMENT TYPE: Journal LANGUAGE: Japanese

AB In vivo expts. with guinea pig corneum and human skin and in vitro tests indicated that an appropriate combination of H2O, humectants and oily substances was important for a max. skin moisturizing effect. The combination showed synergistic effects. Furthermore, appropriate combination of higher mol.-wt. humectants (hyaluronic acid [9004-61-9] and other mucopolysaccharides) and lower mo.-wt. humectants glycerol [56-81-5] and other polyols or (pyrrolidonecarboxylic acid [98-79-3]) also showed synergistic effects. An appropriate formulation protects the skin via physicochem. effects as well as biochem. effects (e.g., promotion of amino acid metab.).

IT 9067-32-7

RL: BIOL (Biological study) (skin moisturizers contg.)

L4 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1984:73782 CAPLUS

DOCUMENT NUMBER: 100:73782

TITLE: Application of water-holding polymers

as a skin moisturizer

AUTHOR(S): Hoshizaki, Sadao; Nakabata, Hidetoshi

CORPORATE SOURCE: Pola Lab., Yokohama, Japan SOURCE: J. SCCJ (1983), 17(1), 19-26

CODEN: JOSCDQ

DOCUMENT TYPE: Journal LANGUAGE: English

Water-sol. polymers forming hydrogel films contg. water provide natural protective characteristics not found in commonly used low-mol. wt. humectants. Film strength and elasticity tests on the polymers resulted in Na hyaluronate (I) [9067-32-7] giving the highest values under all test conditions. In vivo tests and surface slip resistance measurements indicated that I reduced skin friction resistance and thus increased skin smoothness. Transepidermal water loss, and skin/polymer affinity measurements revealed that some water sol. polymers formed, not a completely occlusive, but a water-permeable, dermal respirable film on skin surfaces. In vitro and in vivo test results suggested that ideal water sol. polymers which would be useful as skin moisturizer should meet the following conditions; (A) must have a high mol. wt. rather than a low mol. wt.; (B) should have a component of a N compd. for better skin affinity; I having a mol. wt. in 6 .times. 105 9 .times. 105 range fulfilled all of these conditions. The optimum combination of these properties enhances the skin's natural protective mechanism and is chiefly responsible for its outstanding performance as a skin moisturizer. Also lotions contg. I had a pleasant skin feel and the feel was perceptible at a low level of incorporation by the consumers.

IT 9067-32-7

RL: BIOL (Biological study)
 (skin moisturizer)

FILE MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, 到CST-EPLUS, JAPIO' ENTERED AT 15:07:49 ON 04 APR 2002)

24 S L4 22 DUP REM 15 (2 DUPLICATES REMOVED)

ANSWER 1 OF 22 WPIDS COPYRIGHT 2002 DERWENT INFORMATION LTD

ACCESSION NUMBER:

2000-318801 [28] WPIDS

DOC. NO. CPI:

C2000-096847

TITLE:

Sterilizing liquid containing transparent

sodium hyaluronate for hand

washing - is prepared by dissolving water insoluble non-ionic antibacterial agent in surfactant solution, then addition of wetting

humectant.

DERWENT CLASS:

INVENTOR(S):

D22 E14

HUANG, X; LING, P; YUE, W

PATENT ASSIGNEE(S):

(LING-I) LING P

COUNTRY COUNT:

PATENT INFORMATION:

| PAT | TENT NO | KIND | DATE | WEEK | LA | PG |
|-----|---------|------|----------|------------|----|----|
| | | | | | | |
| CN | 1245213 | Α | 20000223 | (200028) * | | 1 |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|------------|------|----------------|----------|
| | | | |
| CN 1245213 | A | CN 1998-110400 | 19980814 |

PRIORITY APPLN. INFO: CN 1998-110400 19980814

ΑN 2000-318801 [28] WPIDS

1245213 A UPAB: 20000617 AΒ

> A sterilizing liquid containing sodium hyaluronate for washing hands, is prepared by dissolving a water -insoluble nonionic antibacterial agent (for example, 2,4,4'-trichloro-2'-hydroxydiphenyl ether) in aqueous solution containing surfactant, and adding sodium hyaluronate as natural wetting humectant to it.

USE - Hand washing in hospitals, pharmaceutical industry and similar fields.

ADVANTAGE - Broad antibacterial application spectrum, high antibacterial effect, no damage to skin, and beautifying skin by making it smooth and flexible.

ANSWER 2 OF 22 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.-

ACCESSION NUMBER:

2000384444 EMBASE

TITLE:

Therapeutic moisturizers.

AUTHOR:

Draelos Z.D.

CORPORATE SOURCE:

Dr. Z.D. Draelos, 2444 North Main Street, High Point,

NC 27262, United States. zdraelos@northstate.net

SOURCE:

Dermatologic Clinics, (2000) 18/4 (597-607).

Refs: 48

ISSN: 0733-8635 CODEN: DRMCDJ

COUNTRY:

United States

DOCUMENT TYPE:

Journal; General Review

FILE SEGMENT:

Dermatology and Venereology 013

LANGUAGE: English SUMMARY LANGUAGE: English

AB Moisturizers have been adapted to perform many important roles on the skin surface. Simple moisturizers combine occlusives and humectants to enhance the water-holding capacity of the skin. The addition of carefully selected emollients can influence the esthetic properties of the moisturizer and the stability of the active ingredients. The addition of sunscreens to moisturizers has created a new product category with an added skin function. Further diversity in moisturizer formulation is created through the addition of specialty ingredients, designed to enhance the functioning of the skin. Moisturizers are an important part of the dermatologist's armamentarium.

L6 ANSWER 3 OF 22 JAPIO COPYRIGHT 2002 JPO

ACCESSION NUMBER:

1999-279531 JAPIO

TITLE:

GLAND PACKING

INVENTOR:

TANEMOTO MASAHITO; WATANABE KATSUMI; KUZAWA

NAOYA

PATENT ASSIGNEE(S):

NICHIAS CORP)

PATENT INFORMATION:

PATENT NO KIND DATE ERA MAIN IPC

JP 11279531 A 19991012 Heisei C09K003-10

JΡ

APPLICATION INFORMATION

ST19N FORMAT:

JP1998-100103

19980327

ORIGINAL:

JP10100103

Heisei

SOURCE:

PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 99

Applic

AN 1999-279531 **JAPIO** AB PROBLEM TO BE SOLVED: To obtain a gland packing which exhibits a low sliding resistance and good sealing properties by incorporating a humectant and a lubricant (e.g. paraffin) into an expandable graphite packing comprising expandable graphite or a composite thereof with reinforcing fibers (e.g. metal fibres). SOLUTION: A sheet of expandable graphite or of a composite of expandable graphite with reinforcing fibers (e.g. metal fibers) is cut into a certain width; thus obtd. tape-like material is spirally arranged in a metal mold and then press-molded in the longitudinal direction to give a ring-shape expandable graphite gland packing; and this gland packing is immersed in a liquid contg. equal amts. of a humectant and a lubricant selected from among turbine oils, silicone oils, paraffin waxes, paraffin emulsions, etc., to give a gland packing contg. the humectant and the lubricant attached thereto, each in an amt. of 0.1 wt.% or higher. The humectant absorbs the atmospheric moisture and prevents water at the packing surface from vaporizing, and its examples are glycerin, ethylene glycol, glycine, soluble collagen, polypeptides, and sodium hyaluronate. COPYRIGHT: (C) 1999, JPO

L6 ANSWER 4 OF 22 JICST-EPlus COPYRIGHT 2002 JST

ACCESSION NUMBER:

980716649 JICST-EPlus

TITLE:

Synthesis and Application of 2-Methacryloyloxyethyl

Phosphorycholine Copolymer.

AUTHOR: SHIMADA KUNIO; IRIE HIROFUMI; MURATA YOSHISHIGE

ISHIHARA KAZUHIKO NAKABAYASHI NOBUO

CORPORATE SOURCE: Tsukubaken

Univ. of Tokyo, Grad. Sch.

Tokyo Medical and Dental Univ., Inst. for Medical and

Dental Engineering

SOURCE: Fragr J, (1998) vol. 26, no. 7, pp. 97-104. Journal

Code: G0987B (Fig. 13, Tbl. 3, Ref. 8)

CODEN: FUJAD7; ISSN: 0288-9803

PUB. COUNTRY: Japan

DOCUMENT TYPE: Journal; Article

LANGUAGE: Japanese STATUS: New

AB Moisturizing agents such as sodium hyaluronate,

sodium pyrrolidonecarboxylate, or sphingolipid have been developed for use in cosmetic field. Although they show humectant properties with various mechanism, their effect seems to be limited.

We have synthesized an amphiphilic polymer, poly.cents.2methacryloyloxyethyl phosphorylcholine(MPC)-co-butyl methacrylate(BMA)! which not only shows water-holding capacity under both in vitro and in vivo test but also gives us

naturally moisturized feeling on the skin. At the same time, the poly(MPC-co-BMA) works as a surfactant with reducing static electrification and surface tension. It protects hair or skin from damage, rather cures them. In this article, we introduce application of the poly(MPC-co-BMA) to the skin-care and the hair-care cosmetics. For cosmetics field such a less irritating surfactant has

a great promise for future ingredient. (author abst.)

L6 ANSWER 5 OF 22 JICST-EPlus COPYRIGHT 2002 JST

ACCESSION NUMBER: 971029863 JICST-EPlus

TITLE: Skin-softening Effect of Sodium Acetylhaluronate.

AUTHOR: OKA TAKASHI; MATSUZAKI FUMIAKI; YANAKI TOSHIO

CORPORATE SOURCE: Shiseido Co., Ltd.

SOURCE: Nippon Kagakkai Koen Yokoshu, (1997) vol. 73rd, pp.

331. Journal Code: S0493A

ISSN: 0285-7626

PUB. COUNTRY: Japan
LANGUAGE: Japanese
STATUS: New

AB To endow sodium hyaluronate (HA) with precious

functions, we synthesized sodium acetylhyaluronate(AcHA), which has an excellent skin-softening effect for stratum corneum. To clarify the mechanism of the effect, differential scanning calorimetry(DSC) unveiled that the maximum bound water content, which is observed before appearance of free water, of AcHA wasequal to that of HA. However, DSC also showed that the bound water content of stratum corneum treated with AcHA was markedly greater than that of HA-treated stratum corneum. To investigate this interaction, the adsorption of AcHA on human skin was measured. The results showed that the amount of adsorption of AcHA was markedly greater than that of HA. Considering these results and properties, it was suggested that AcHA could be adsorbed efficiently on human skin, and this adsorption reduced the transepidermal water loss and resulted in the skin-softening effect. Upon the use of AcHA in cosmetic formula, it was observed that a lotion containing 0.2% AcHA could increase the water contents in stratum corneum,

reduce the transepidermal water loss(TEWL), and improve the skin condition. Although further research is necessary to demonstrate the skin-softening effect of AcHA, its superior effect as a humectant was confirmed in this study. (author abst.)

JICST-EPlus COPYRIGHT 2002 JST. ANSWER 6 OF 22

ACCESSION NUMBER:

970431514 JICST-EPlus

TITLE:

Skin Care in Atopic Dermatitis. Characterizing dry skin in atopic dermatitis and utility of skin care.

AUTHOR:

TAKAHASHI MOTOJI

CORPORATE SOURCE:

Shiseido Co., LTD

SOURCE:

Nippon Koshohin Kagakkaishi (Journal of Japanese Cosmetic Science Society), (1997) vol. 21, no. 1, pp. 50-55. Journal Code: Y0265A (Fig. 6, Tbl. 2, Ref. 14)

ISSN: 0287-1238

PUB. COUNTRY:

Japan

DOCUMENT TYPE:

Journal; Commentary

LANGUAGE:

Japanese

STATUS: New AΒ The dry skin in atopic dermatitis (AD) was characterized using non-invasive methods. Patients with atopic xerosis showed markedly higher transepidermal water loss (TEWL) and markedly lower skin surface hydration levels than did the controls. The stratum corneum of AD patients contained lower amount of free amino acids and ceramides than did those of controls. Skin surface pH in AD patients was higher than that of controls. Parakeratotic cells were observed in tape stripped stratum corneum of AD patients. A clinical study of cream which is compounded of squalane and jojoba oil as the main bases, a derivative of glycyrrhetic acid and allantoin as the active ingredients, and sodium hyaluronate and glycerin as the humectant was conducted for patients with mild to moderate AD to evaluate its utility. The rate of improvement by symptom was especially high, 78.4 and 75.0%, for dry skin and scale, respectively, and the rates for an itching sensation and scratch marks were also relatively high, 56.1 and 53.1%, respectively. The physiological condition of AD skin was improved by 4 weeks treatment by the cream. Moisture content of stratum corneum significantly increased and the heterogenecity of skin surface ridges significantly decreased. TEWL tended to be lower after use than before use. The effect of 4 weeks treatment by bathing emulsion containing oil, humectants, dipotassium glycyrrhetinate, and rice germ oil on AD dry skin was examined. The rate of improvement by symptom was high, 74.2% for dry skin and scale, and the rates for an itching sensation was 54.8%. By the measurement of skin surface conductance it was appeared that the use of bathing emulsion tends to help retain more moisture than non-use. In conclusion, skin care treatment (use of cream or bathing emulsion)

ANSWER 7 OF 22 JICST-EPlus COPYRIGHT 2002 JST

self-medication in AD patients. (author abst.)

ACCESSION NUMBER:

971032777 JICST-EPlus

is useful for improvement of clinical symptoms and for

TITLE:

New raw materials and technologies for cosmetics. Development and application of Acetylhyaluronate for

cosmetics, a novel humectant having an

excellent skin-softening effect for stratum corneum.

AUTHOR:

OKA TAKASHI; YANAKI TOSHIO

CORPORATE SOURCE:

Shiseido Co., LTD

Fragr J, (1997) vol. 25, no. 10, pp. 9-15. Journal SOURCE:

Code: G0987B (Fig. 16, Ref. 18)

CODEN: FUJAD7; ISSN: 0288-9803

PUB. COUNTRY:

Japan

DOCUMENT TYPE: Journal; Commentary

LANGUAGE:

Japanese

STATUS:

New

AΒ To endow sodium hyaluronate (HA) with precious functions, we synthesized sodium acetylhyaluronate(AcHA), which was found to have a superb moisturizing effect and has an excellent skin-softening effect. To clarify mechanism of the effect, the hydration and adsorption of AcHA for the stratum corneum were measured. The results indicated that AcHA increased the water content in stratum corneum and could be efficiently adsorbed on the stratum corneum. Consequently, AcHA reduced transepidermal water loss(TEWL) and sufficiently softened the stratum corneum. Upon the use of AcHA in a cosmetic formula, it was also observed that 0.2% AcHA-lotion could increase the water contents in stratum corneum, reduce the TEWL, and

improve scaly dry skin condition. (author abst.) ANSWER 8 OF 22 JAPIO COPYRIGHT 2002 JPO

ACCESSION NUMBER:

1996-291057 JAPIO

TITLE:

. CATAPLASM

INVENTOR:

MIYAJIMA YOSHIHARU

PATENT ASSIGNEE(S):

YUUTOKU YAKUHIN KOGYO KK, JР (CO 463909)

PATENT INFORMATION:

PATENT NO KIND DATE ERA MAIN IPC Heisei (6) A61K009-70 19961105 JP 08291057 Ā

JP.

SOURCE:

APPLICATION INFORMATION

ST19N FORMAT:

JP1996-44028

19960207

ORIGINAL:

JP08044028

Heisei PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined

Applications, Vol. 96, No. 11

ΑN 1996-291057 **JAPIO**

PURPOSE: To obtain a cataplasm capable of exhibiting extremely AB excellent skin-protecting effect without using a pharmaco dynamic component such as an antiinflammatory analgesic agent which is conventionally compounded and effective for curing xeroderma, etc., by compounding a base material having a high content of water with a specific humectant component.

CONSTITUTION: (A) A cataplasm base material (preferably, consisting of 10-20wt.% of a base material, 10-25wt.% of a polyvalent alcohol, 2-13wt.% of a water-soluble high molecular compound and 30-80wt.% of water, and having a pH of 4.2-6.4) is compounded with (B) at least one kind of humectant selected from (i) sodium hyaluronate, (ii) sodium chondroitinsulfate, (iii) a lactic acid salt, (iv) pyrrolidonecarboxylic acid, (v) urea, (vi) an aloe extract and (vii) an extract of leaves of a beefsteak plant. Further, 0.1-1wt.% of the component (ii), 0.01-0.1wt.% of the component (i) or 1-5wt.% of the component (v) is preferably used as the component B, each based on

the component A. Especially, it is preferable to use the combination of the components (ii), (i) and (v) as the component B.

> 308-4994 Searcher : Shears

ANSWER 9 OF 22 JAPIO COPYRIGHT 2002 JPO L6 ACCESSION NUMBER: 1996-012571 **JAPIO**

DISINFECTING LIQUID FOR EXTERNAL USE TITLE:

MIYANO SHIGERU; OKUMA TAKAAKI; HINO YASUHIKO; **INVENTOR:**

YAMAZAKI EMIKO; KOMURO CHIKARA

PATENT ASSIGNEE(S): NIPPON KAYAKU CO LTD, JP (CO 000408)

PATENT INFORMATION:

PATENT NO KIND DATE ERA MAIN IPC 19960116 Heisei (6) A61K031-14 JP 08012571 A

JP

APPLICATION INFORMATION

JP1995-53744 19950220 ST19N FORMAT: JP07053744 Heisei ORIGINAL:

SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined

Applications, Vol. 96, No. 1

1996-012571 **JAPIO** AN

PURPOSE: To obtain a disinfecting liquid for external use containing AΒ an alkylbenzyldimethylammonium and a water-soluble negatively charged polymer as essential ingredients, excellent in humectant properties for preventing hands from roughening. CONSTITUTION: This disinfecting liquid for external use comprises (A) an alkylbenzyldimethylammonium or its salt (preferably, benzalkonium chloride or benzethonium chloride) and (B) a water-soluble negatively charge polymer and/or its salt (preferably, hyaluronic acid or its salt) as essential ingredients, and (C) 30-65wt./vol.% an aqueous solution of ethanol as a preferable solvent. The concentrations of the ingredients are preferably 0.05-0.5 (wt./vol.)% ingredient (A), 0.001-0.3 (wt./vol.)% ingredient (B) and 30-60 (wt./vol.)% ingredient (C). The disinfecting liquid for external use comprises, e.g. 40-60 (wt./vol.)% aqueous solution of ethanol containing 0.1-0.3 (wt./vol.)% benzalkonium chloride or benzethonium chloride, 0.002-0.05 (wt./vol.)% sodium hyaluronate or sodium hyaluronate and succinylated carboxymethylchitosan.

ANSWER 10 OF 22 JICST-EPlus COPYRIGHT 2002 JST L6

961012948 JICST-EPlus ACCESSION NUMBER:

Moisturizing and Skin-softening Effect on Sodium TITLE:

Acetylhyaluronate.

AUTHOR: OKA TAKASHI; YANAKI TOSHIO; YAMAGUCHI MICHIHIRO

CORPORATE SOURCE: Shiseido Co., Ltd.

Nippon Kagakkai Koen Yokoshu, (1996) vol. 71st, pp. SOURCE: - -

80. Journal Code: S0493A

ISSN: 0285-7626

PUB. COUNTRY:

Japan LANGUAGE: Japanese STATUS: New

AΒ To maintain healthy and fresh skin, it is necessary to moisten sufficiently the stratum corneum. Due to aging, surroundings, physical constitution, and other factors, the stratum corneum always has a tendency to lose its normal water content. It is effective to apply the humectant to the skin for keeping the normal water content. In general humectants,

sodium hyaluronate(HA) has a very highly
moisturizing effect. To endow HA with precious functions, we
synthesized varieties of HA derivatives and evaluated their
usefulness for cosmetic products. After numerous investigations for
finding HA derivatives, we eventually discovered a novel HA
derivative, sodium acetylhyaluronate(AcHA), which has a very highly
skin-softening effect for the stratum corneum. Moreover, many
physicochemical studies on AcHA showed that the hygroscopic property
of AcHA is equal to that of HA. We also observed that AcHA has an
effect of lowering the surface tension, an effect of holding
water to the skin, an effect of improving the rough and dry
skin, a very highly ethanol-solubility, and other functions. (author
abst.)

L6 ANSWER 11 OF 22 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

DUPLICATE 1

ACCESSION NUMBER: 1996:273748 BIOSIS DOCUMENT NUMBER: PREV199698829877

TITLE: Clinical study of ADS cream (medicated Atskin Cream)

in atopic dermatitis.

AUTHOR(S): Ikezawa, Zenroh (1); Kitamura, Kazuko; Komatsu,

Taira; Sugiyama, Asami; Ohsawa, Junko

CORPORATE SOURCE: (1) Dep. Dermatol., Yokohama City Univ. Urafune Hosp.

3-46, Urafune-cho, Minami-ku, Yokohama-City 232 Japan

SOURCE: Skin Research, (1996) Vol. 38, No. 1, pp. 74-96.

ISSN: 0018-1390.

DOCUMENT TYPE: Article LANGUAGE: Japanese

SUMMARY LANGUAGE: Japanese; English

A clinical study of ADS cream (medicated Atskin cream) which is compounded of squalane and jojoba oil as the main bases, a derivative of glycyrrhetic acid and allantoin as the active ingredients, and sodium hyaluronate as the humectant was conducted in 99 patients with mild to moderate atopic dermatitis (AD) to evaluate utility. The rate of improvement which was determined from general improvement rating was 35.4% (including evaluations classified as "moderately and remarkably improved") and 78.8% (including evaluations classified as "slightly, moderately, and remarkably improved"). The rate of improvement by symptom was especially high, 78.4% and 75.0%, for dry skin and scale, respectively, and the rates for an itching sensation and scratch marks were also relatively high, 56.1% and 53.1% respectively. Adverse reactions to this cream were reported in 3 patients (3.0%), the symptoms consisting of a tingling sensation in 1 patient, itching, erythema, and papule in 1 patient, and papule in 1 patient. The rate of utility which was determined in consideration of the general improvement rating and adverse reactions was high, 42.4% (including evaluations classified as "moderately and very useful") and 75.8% (including evaluations classified as "slightly, moderately, and very useful"). To evaluate the effect of ADS cream on the physiological condition of skin in a non-invasive way, the moisture content of the stratum corneum (corneous conductance), transepidermal water loss (TWL), and skin surface morphology (VC1: a parameter showing the radial heterogeneity of a skin fissure) were determined. Apart from the above-mentioned study, 23 patients with mild to moderate AD were given ADS cream for about 4 weeks to evaluate the dermato-physiological parameters and its .clinical effect. The rate of improvement which was determined from

the general improvement rating was 43.5% (including evaluations classified as "moderately and remarkably improved") and 73.9% (including evaluations classified as "slightly, moderately, and remarkably improved"). The rate of improvement by symptom was more than 70.0% for dry skin, scale, and scratch marks, more than 60% for erythema and pauple, and more than 50% for an itching sensation. These findings roughly coincide with those obtained in the previous study (in 99 subjects). The results of dermato-physiological parameter measurement indicate an improvement in the physiological condition of the stratum corneum, as shown by a significant increase in the moisture content of the stratum corneum (p lt 0.05) and a significant decrease in fissural heterogeneity (p lt 0.05). In addition, the mean value of TWL tended to be slightly lower after use than before use, though there was no significant difference, i.e., improvement in skin surface barrier function was suggested. In conclusion, the results presented suggest that ADS cream may be useful as skin care cream intended for self-medication in AD patients because clinical symptoms, the moisture content of the stratum corneum, and skin surface morphology were improved in such patients by the use of it.

ANSWER 12 OF 22 JICST-EPlus COPYRIGHT 2002 JST

ACCESSION NUMBER:

950262990 JICST-EPlus

TITLE:

Special issue : Dyeing without pollution. Hyaluronic

acid, which is spotlighted.

SOURCE:

Kako Gijutsu, (1995) vol. 30, no. 3, pp. 163-165.

Journal Code: G0791B (Fig. 7, Tbl. 1)

ISSN: 0386-6041

PUB. COUNTRY:

Japan

DOCUMENT TYPE:

Journal; Commentary

LANGUAGE:

Japanese

STATUS:

New

Composition, features, and physical properties of hyaluronic acid AB FCH of KIBUN FOOD CHEMIFA Co., Ltd. is introdeuced. It is polymeric sodium hyaluronate obtained by fermentation using streptococcus Streptococcus zooepidemicus. Hyaluronic acid is a cosmetic humectant with high moist retention in low humidity atmosphere, and causes no skin impediment. The application to fiber is being examined.

ANSWER 13 OF 22 WPIDS COPYRIGHT 2002 L6

DERWENT INFORMATION LTD

ACCESSION NUMBER:

1994-068304 [09] WPIDS

DOC. NO. CPI:

C1994-030476

TITLE:

Hyaluronidase inhibitors for addn. to cosmetics and

quasi drugs - contain solvent extract of e.g. fruit, buds, bark roots or stems of plants.

DERWENT CLASS: -

B04 D21

PATENT ASSIGNEE(S):

(MIKI-N) MIKIMOTO SEIYAKU KK

COUNTRY COUNT:

PATENT INFORMATION:

KIND DATE PG PATENT NO WEEK LAA 19940118 (199409)* JP 06009371

APPLICATION DETAILS:

PATENT NO KIND APPLICATION DATE

JP 06009371 A JP 1992-187453 19920623

PRIORITY APPLN. INFO: JP 1992-187453 19920623

1994-068304 [09] WPIDS AN

JP 06009371 A UPAB: 19940418 AB

Hyaluronidase inhibitors comprise one or more of solvent extracts selected from the fruit of Terminalia chebula Retz, the rhizome of Dryopteris Crassirhizoma Nakai, bark or peel of Punica granatum L., bud of Eugenica caryophillata (or Syzygium aromaticum), fruit of Areca catechu L., bark of Fraxinus japonica (F. lanuginosa, or F. rhynchophylla), root of Berchemica lineata D.C., bark of Wikstroemia indica C.A. Mey and stem of Ephedra sinica Stapf.

Specifically solvents employed are water, ethanol, or their mixts. with polyvalent alcohols. Oils, humectants, and other ingredients may be added and a variety of cosmetic formulations can be possible, e.g. lotion, cream, emulsion and pack.

USE/ADVANTAGE - The solvent extract, when added at about 0.01% inhibit the decompsn. of hyaluronic acid and, therefore, are useful as additives of no toxicity to cosmetics and quasi drugs. Hyaluronic acid can hold water in the gap of cells and form jelly-like matrix in the tissue, thus maintaining lubricity and elasticity of the skin, blocking the influence from outside and infections of bacteria, and preventing wrinkles and roughness of the skin.

In an example, dried T. chebula (10 g) was stood in 300 ml ethanol with occasional stirring, filtered, and lyophilised to prepare an ethanol ext.. A mixt. of 0.5% olive oil, 0.5% the ethanol ext., 2.0% polyoxyethylene (20E.O.) sorbitan monostearate, 2.0% polyoxyethylene (60E.O.) hardened caster oil, 10.0% ethanol, 5.0% Na hyaluronate 1.0% aq. soln., and 80.0% pure water was made into a lotion. Dwq.0/0

ANSWER 14 OF 22 WPIDS COPYRIGHT 2002 DERWENT INFORMATION LTD L6 WPIDS

ACCESSION NUMBER: DOC. NO. CPI:

1994-272996 [34]

TITLE:

C1994-124852

Novel D-galacturonic acid L-rhamnose +D-glucose

contg. polysaccharide(s) - useful as humectants, emulsifiers, dispersion,

stabilisers, foam stabilisers, and cement additives

etc.

DERWENT CLASS:

A11 D13 D16 D17 D21 L02

INVENTOR(S):

MISAKI, A; NAKAGAWA, M; NAKANISHI, O; OKUMIYA, T;

OOISO, Y; SUGIHARA, R

PATENT ASSIGNEE(S):

(TKAK) TAYCA CORP

COUNTRY COUNT:

PATENT INFORMATION:

| PAT | TENT NO | KIND | DATE | WEEK | LA | PG |
|-----|----------|------|----------|-----------|----|----|
| EP | 613951 | A2 | 19940907 | (199434)* | EN | 17 |
| | R: DK F | | _ | | | |
| JΡ | 07090003 | Α | 19950404 | (199522) | • | 11 |
| EΡ | 613951 | . A3 | 19950628 | (199611) | | |
| US | 5508190 | Α | 19960416 | (199621) | | 11 |
| US | 5527904 | Α | 19960618 | (199630) | | 11 |

.10/038830

APPLICATION DETAILS:

| PA | TENT NO | KIND | | AP | PLICATION | DATE |
|----|--------------------|---------|--------|----|----------------------------|----------------------|
| | 613951 07090003 | A2 A | | | 1994-102795 1993-308620 | 19940224 19931115 |
| ΕP | 613951 | А3 | | EP | 1994-102795 | 19940224 |
| US | 5508190 | A | Div ex | US | 1994-201698 | 19940225 |
| | | | | US | 1995-404642 | 19950315 |
| US | 5527904 | Α | | US | 1994-201698 | 19940225 |

PRIORITY APPLN. INFO: JP 1993-64681 19930301; JP 1993-207046 19930729; JP 1993-308620 19931115

AN 1994-272996 [34] WPIDS

AB EP 613951 A UPAB: 19941013

Novel polysaccharides (I) have the following physicochemical props.; (a) mol.wt. 5x103 to 10x106; (b) constituent glycoses alpha-D-galacturonic acid, beta-L-rhamnose, and alpha-D-glucose; and (c) constituent glycoses joined substantially by 1,3-linkages.

USE - (I) Have excellent H2O-retaining ability which is almost completely unaffected by the ambient relative humidity (unlike e.g. Na hyaluronate). (I) also have: film-forming properties, when they form a colourless, transparent and tough film useful for packaging and coating (in partic. a film from deacetylated (I) has excellent tensile strength and elongation at break); and dispersion-stabilising properties, useful as low-viscosity replacements for gum arabic. (I) are also useful as emulsifiers, humectants, and foam stabilisers, and in cement mixts., etc.

Dwg.0/2

ABEQ US 5508190 A UPAB: 19960529

An isolated Azotobacter Beijerinkii TNM1 (FERM BP-4194) or a mutant thereof which is capable of producing polysaccharides having the following physicochemical properties:

- (1) a molecular weight determined by gel filtration chromatography is about 5multiplied by103 to 10multiplied by106,
- (2) the constituent glycoses are D-galacturonic acid, L-rhamnose and D-glucose,
- (3) the constituent glycoses are joined substantially by 1,3-linkages, and
- (4) a configuration of D-galacturonic acid is alpha, that of L-rhamnose is beta and that of D-glucose is alpha.

ABEQ US 5527904 A UPAB: 19960731

Polysaccharides having the following physicochemical properties: (1) a molecular weight determined by gel filtration chromatography is about 5 x 103 to 10 x 106, (2) the constituent glycoses are D-galacturonic acid, L-rhamnose and D-glucose, (3) the constituent glycoses are joined by 1,3-linkages, and (4) a configuration of D-galacturonic acid is alpha, that of L-rhamnose is beta and that of D-glucose is alpha.

Dwg.0/2

L6 ANSWER 15 OF 22 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 95006265 EMBASE

DOCUMENT NUMBER: 1995006265

TITLE: Enhanced substantivity of hyaluronic acid on keratin

substrates via polymer complexation.

AUTHOR: Pavlichko J.P.; Goddard E.D.; Band P.A.; Leschiner A.

CORPORATE SOURCE: Amerchol Corporation, 136 Talmadge Road, Edison NJ

08818-4051, United States

SOURCE: International Journal of Cosmetic Science, (1994)

16/6 (227-234).

ISSN: 0142-5463 CODEN: IJCMDW

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 013 Dermatology and Venereology

023 Nuclear Medicine 030 Pharmacology

037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English; French

AB Complexes of glycosaminoglycans and certain cationic polymers have been identified which provide utility in skin and hair care applications. The combination of biologically engineered hyaluronic acid and the cationic cellulose polymer, polyquaternium-10, results in a unique, stable, multifunctional, association complex with enhanced polymer functionality. Complexation of the anionic and cationic polysaccharide polymers renders hyaluronic acid substantive to keratin, as evidenced by zeta potential changes of the surface charge of hair via electrokinetic streaming potential measurements. Radiolabelling techniques show as much as a ten-fold increase in bound hyaluronic acid on hair after water rinsing. The resulting 'enhanced' substantivity of hyaluronic acid, as part of the complex, thus extends the time hyaluronic acid remains in contact with keratinous surfaces, prolonging its humectant, moisturizing and skin-smoothening effects.

L6 ANSWER 16 OF 22 WPIDS COPYRIGHT 2002 DERWENT INFORMATION LTD

ACCESSION NUMBER:

1993-392559 [49] WPIDS

DOC. NO. CPI:

C1993-174610

TITLE:

Lubricant for vaginal cavity - composed of polyarylamide and glycerine together with humectant, bactericide and antifungal

agent.

DERWENT CLASS:

A96 B07 C07

PATENT ASSIGNEE(S):

(OKAM-N) OKAMOTO CO LTD

COUNTRY COUNT:

PATENT INFORMATION:

PATENT NO KIND DATE WEEK LA PG

JP 05294825 A 19931109 (199349)* 4

APPLICATION DETAILS:

PATENT NO KIND APPLICATION DATE

JP 05294825 A JP 1992-98119 19920417

PRIORITY APPLN. INFO: JP 1992-98119 19920417

AN 1993-392559 [49] WPIDS

AB JP 05294825 A UPAB: 19940126

Lubricant is composed of a polyacrylamide and glycerine added with a

humectant, an antibacterial and an antifungal agents. In water, 0.5-5.0% of a polyacrylamide, 1.0-10% glycerine, 0.01% humectant (e.g. Na hyaluronate and Na alginate), 0.1-0.5% antifungal agent (e.g. imidazoles and thiabenzazoles), 0.01-0.375% alkyl p-hydroxybenzoate, and 0.01-1.00% of a surfactant were added to give the lubricant jellies having 150-2000 cps.. The jellies are filled in a container together with 50-30 v/v% of CO2 at 5-8 kg/cm2. USE/ADVANTAGE - A lubricant for smooth coitus and vaginal cavity.

In an example, in 95.1 pts. purified water, 1.25 pts. polyacrylamide was dissolved in 20-30 mins. with stirring. In glycerine warmed at 65-70 deg.C, 0.025 pt. of propyl p-hydroxybenzoate and 0.075 pt. of methyl p-hydroxybenzoate were mixed portionwise in 20 mins.. In water, 0.05% of Na hvaluronate, 0.2% of a sugar ester and 0.3% of a thiabenzazole were dissolved separately. The resultant solns. were mixed gently and allowed to stand overnight to give a jelly compsn.. The compsn. was filled in a container together with CO2 at 5.6 kg/cm2. Dwq.0/0

ANSWER 17 OF 22 JAPIO COPYRIGHT 2002 JPO

ACCESSION NUMBER:

1993-345711 JAPIO

TITLE:

SKIN PROTECTION AGENT

INVENTOR:

MASAKI HITOSHI; TAKEI MASUMI

PATENT ASSIGNEE(S):

NOEVIR CO LTD, JΡ (CO 490382)

PATENT INFORMATION:

| PATENT NO | 11110 | ERA | MAIN | 110 |
|-------------|-------|---------|------|------------|
| JP 05345711 | | | | A61K007-40 |

JP

APPLICATION INFORMATION

ORIGINAL:

ST19N FORMAT:

JP1991-100427

19910404 JP03100427 Heisei

SOURCE:

PATENT ABSTRACTS OF JAPAN, Unexamined

Applications, Section: C, Sect. No. 1186, Vol.

18, No. 191, P. 63 (19940404)

AN 1993-345711 JAPIO

AΒ PURPOSE: To provide a skin-protection agent capable of forming a tack-free water-insoluble film of chitosan on the skin to effectively protect the skin from chapping without lowering the operability in work.

CONSTITUTION: A water-insoluble chitosan film is formed on the skin by combining (A) an aqueous solution of an acid salt of chitosan or a water-soluble chitosan derivative selected from carboxylated compound, sulfonated compound, glycolated compound or quaternized compound of chitosan with (B) a dilute alkaline aqueous solution or an aqueous solution of a polymeric compound having charge opposite to the charge of the chitosan derivative. The agent may be incorporated with a huwectant component such as sodium hyaluronate. The film gives moist

feeling to the skin without causing tackiness and the lowering of the operability in work. The chitosan film can easily be removed by washing with an weakly acidic aqueous solution or an aqueous solution of an anionic substance or a cationic substance.

> 308-4994 Shears Searcher :

L6 ANSWER 18 OF 22 JAPIO COPYRIGHT 2002 JPO ACCESSION NUMBER: 1990-215707 JAPIO

TITLE: SKIN COSMETIC

INVENTOR: SUZUKI ERIKO; HIRAKI JUN; FUJII MASAHIRO

PATENT ASSIGNEE(S): CHISSO CORP, JP (CO 000207)

PATENT INFORMATION:

PATENT NO KIND DATE ERA MAIN IPC

JP 02215707 A 19900828 Heisei (5) A61K007-00

JP

APPLICATION INFORMATION

ST19N FORMAT: JP1989-33791 19890215
ORIGINAL: JP01033791 Heisei

SOURCE: PATENT ABSTRACTS OF JAPAN, Unexamined

Applications, Section: C, Sect. No. 778, Vol.

14, No. 522, P. 31 (19901115)

AN 1990-215707 JAPIO

PURPOSE: To obtain a skin cosmetic having good compatibility with AB water, no rough feeling in application to the skin and both humectant action and skin beautifying effects by using a lyophilized product of an aqueous solution containing hyaluronic acid (salt) and phosphate-L-ascorbin magnesium. CONSTITUTION: A lyophilized product of an aqueous solution of hyaluronic acid or sodium hyaluronate and phosphate-L-ascorbin magnesium shown by the formula in the weight ratio of the former and the latter of 1:0.1-50 is used as a cosmetic raw material of powder side of a two-agent type cosmetic comprising toilet lotion and powder. The lyophilized product slightly causes an undissolved lump of powder compared with powder of hyaluronic acid (salt) alone, is dissolved in a shorter time than the powder and is also dissolved in a shorter time than phosphate-L-ascorbin magnesium powder or granule.

L6 ANSWER 19 OF 22 JAPIO COPYRIGHT 2002 JPO ACCESSION NUMBER: 1990-134315 JAPIO

TITLE: BATHING AGENT INVENTOR: KITA KIYOSHI

PATENT ASSIGNEE(S): KITA KIYOSHI, JP (IN)

PATENT INFORMATION:

PATENT NO KIND DATE ERA MAIN IPC

JP 02134315 A 19900523 Heisei (5) A61K007-50

JP

APPLICATION INFORMATION

ST19N FORMAT: JP1988-285733 19881114 ORIGINAL: JP63285733 Heisei

SOURCE: PATENT ABSTRACTS OF JAPAN, Unexamined

Applications, Section: C, Sect. No. 747, Vol.

14, No. 37, P. 42 (19900810)

AN 1990-134315 JAPIO

AB PURPOSE: To obtain a bathing agent, improved in humectant effects and capable of providing glossy skin touch and keeping beautifying function by blending hyaluronic acid with other

ingredients.

CONSTITUTION: A bathing agent obtained by preparing an aqueous solution of, e.g., sodium hyaluronate having 100000-2000000 molecular weight, blended in 10g/l concentration, mixing and using 100ml resultant solution in 400l hot water or mixing and dissolving 1g powdery hyaluronic acid in 4001 hot water. The sodium hyaluronate is obtained by extracting from a cockscomb or fermentation and production from starch using streptococci of the genus Streptococcus. The hyaluronic acid is mixed and used in hot water during bathing to cover the keratinous layer of the skin with the hyaluronic acid holding water. Thereby, systemic humectant effects are provided.

ANSWER 20 OF 22 JAPIO COPYRIGHT 2002 JPO

ACCESSION NUMBER:

1990-062814

TITLE:

POWDERY COSMETIC

INVENTOR:

SUZUKI ERIKO; HIRAKI JUN; FUJII MASAHIRO

CHISSO CORP, JP (CO 000207)

PATENT ASSIGNEE(S): PATENT INFORMATION:

> ERA MAIN IPC PATENT NO KIND DATE JP 02062814 A 19900302 Heisei (5) A61K007-00

JΡ

APPLICATION INFORMATION

ST19N FORMAT: JP1988-212594

19880829

ORIGINAL:

JP63212594

Heisei

SOURCE: PATENT ABSTRACTS OF JAPAN, Unexamined

Applications, Section: C, Sect. No. 721, Vol.

14, No. 242, P. 50 (19900523)

ΑN 1990-062814 JAPIO

PURPOSE: To obtain a powdery cosmetic having humectant AB effect as well as skin-beautifying effect and giving agreeable feeling to the skin by using hyaluronic acid or sodium hyaluronate and an L-ascorbic acid derivative as essential components.

CONSTITUTION: The objective cosmetic contains a complex of hyaluronic acid or sodium hyaluronate and L-ascorbyl magnesium phosphate. The amount of the L-ascorbyl magnesium phosphate is 0.1-10 pts. per 1 pt. of hyaluronic acid. A precipitant such as methanol is added to a solution of the above mixture under stirring and the precipitate is crushed, e.g., in wet state to obtain the objective fine powder having particle diameter of 0.5-40.mu.m. The cosmetic is quickly soluble in water or cosmetic on the palm and applicable to the skin without giving rough feeling nor entering into the pores of the skin.

ANSWER 21 OF 22 JAPIO COPYRIGHT 2002 JPO

ACCESSION NUMBER:

1984-110612 **JAPIO**

TITLE:

HAIR TREATMENT

INVENTOR:

SOTOOKA NORIAKI

PATENT ASSIGNEE(S):

POLA CHEM IND INC, JP (CO 323902)

PATENT INFORMATION:

PATENT NO KIND DATE ERA MAIN IPC

JP 59110612 A 19840626 Showa (3) A61K007-06

JΡ

APPLICATION INFORMATION

19821215 JP1982-219686 ST19N FORMAT: Showa ORIGINAL: JP57219686

PATENT ABSTRACTS OF JAPAN, Unexamined SOURCE:

Applications, Section: C, Sect. No. 247, Vol. 8,

No. 2251, P. 92 (19841016)

1984-110612 JAPIO ΑN

PURPOSE: To provide a treatment containing a hyaluronic acid having AΒ specific molecular weight, capable of restoring and protecting damaged hair, improving and keeping the set hair, and giving glossiness to the hair. CONSTITUTION: Hyaluronic acid having a molecular weight of

500,000-2,000,000 and/or its salt, especially preferably sodium hyaluronate is added to a hair treatment in an amount of 0.005-2wt%. The treatment is preferably the one containing 2-5wt% of humectant, 3-30wt% of lubricant (preferably 5-20wt% of polar lubricant or 5-30wt% of non-polar lubricant), 0-5wt% of surface active agent and 95-15wt% of water as essential components, and having a pH of 4-10, especially 5-9.

ANSWER 22 OF 22 JAPIO COPYRIGHT 2002 JPO L6**JAPIO**

2000-264814 ACCESSION NUMBER:

SKIN LOTION TITLE:

ISHIDA MISAKI; SATOU SAORI; HAYASHI SHINJI INVENTOR:

NOF CORP) PATENT ASSIGNEE(S):

PATENT INFORMATION:

PATENT NO KIND DATE ERA MAIN IPC . JP 2000264814A 20000926 Heisei A61K007-00

JΡ

APPLICATION INFORMATION

JP1999-071251 19990317 ST19N FORMAT: JP11071251 Heisei ORIGINAL:

PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined SOURCE:

Applications, Vol. 2000

ΑN 2000-264814 JAPIO

PROBLEM TO BE SOLVED: To obtain a skin lotion having a light touch AB at the time of use, without causing stickiness even after the use, excellent in humectant effects and persistence of the humectant effects and improving effects on skin roughening and further-in wrinkle eliminating effects, etc., by including an extracted essence of Akebiae Caulis and acidic mucopolysaccahrides in a specific proportion.

SOLUTION: This skin lotion is obtained by including 0.00005-2 wt.% of an extracted essence of Akebiae Caulis expressed in terms of a dry residue and (B) 0.001-3 wt.% of acidic mucopolysaccharides such as sodium hyaluronate in ≥1/100 weight ratio of the ingredients A/B. The ingredient A is prepared by directly thermally refluxing a lianous stem of the Akebiae Caulis together with water, etc., or dipping the lianous stem in

water, etc., or drying the lianous stem and then thermally refluxing the dried lianous stem together with water,

etc., or dipping the dried lianous stem in water, etc. The skin lotion is excellent in stability with time and even restoring properties from preservation at low temperatures. COPYRIGHT: (C) 2000, JPO

'REGISTRY' ENTERED AT 15:10:09 ON 04 APR 2002 Claims 4-8 E BUTYLENE GLYCOL/CN 5 3 S E3 L7 => e peg8 dimethicone/cn 5 F.11 PEG2 PROTEIN KINASE/CN PEG2 PROTEIN KINASE (XENOPUS LAEVIS CLONE XLEG265)/CN E2 1 E3 0 --> PEG8 DIMETHICONE/CN PEGA/CN F.4 2 PEGA 200/CN E5 1 => e "peg 8 dimethicone"/cn 5 E1 1 PEG 7M/CN PEG 8 DILAURATE/CN E2 1 0 --> PEG 8 DIMETHICONE/CN E3 PEG 8 STEARATE/CN E41 E_5 1 PEG 8000/CN => e "peg-8 dimethicone"/cn 5 PEG-6 OLEATE/CN E11 PEG-6 PALMITATE/CN E2 1 E3 0 --> PEG-8 DIMETHICONE/CN E4 PEG-BP 30/CN 1 E5 1 PEG-DESMODUR W COPOLYMER/CN => e polyethylene glycol 8 dimethicone/cn 5 E1 POLYETHYLENE GLYCOL 4000 MONOSTEARATE/CN 1 POLYETHYLENE GLYCOL 4000-VINYL ACETATE-ACRYLIC ACID CO F.2 1 POLYMER/CN E3 0 --> POLYETHYLENE GLYCOL 8 DIMETHICONE/CN POLYETHYLENE GLYCOL 8-HYDROXYQUINOLINE ETHER/CN E41 **E**5 POLYETHYLENE GLYCOL ABIETATE/CN => e polyethylene glycol dimethicone/cn 5 POLYETHYLENE GLYCOL DIMETHACRYLATE-VINYLPYRROLIDONE CO E1 POLYMER/CN POLYETHYLENE GLYCOL DIMETHACRYLATE-VINYLPYRROLIDONE PO E2 LYMER/CN E3 --> POLYETHYLENE GLYCOL DIMETHICONE/CN E41 POLYETHYLENE GLYCOL DIMETHOXYMETHYLSILYLPROPYL ETHER A CETATE/CN 1 POLYETHYLENE GLYCOL DIMETHYL 2-(5-CARBOXYPENTYLAMINO) -S-TRIAZINE-4, 6-DIYL ETHER BARIUM SALT/CN => e "dimethicone, polyethylene glycol"/cn 5 E1 DIMETHICONE, MIXT. WITH DI-ME ME HYDROGEN POLYOXYALKYL ENEPOLYSILOXANES/CN DIMETHICONE, MIXT. WITH PANCREATIN/CN E2 0 --> DIMETHICONE, POLYETHYLENE GLYCOL/CN E3 DIMETHICONE, POLYMER WITH 2-PROPENOIC ACID/CN E4 1 DIMETHICONE, POLYMER WITH AZIRIDINE, GRAFT/CN E.5 1 => e "dimethicone, peg"/cn 5

| | MIXT. WITH DI-ME ME HYDROGEN POLYOXYALKYL | | | | | | | |
|---|--|--|--|--|--|--|--|--|
| E2 1 DIMETHICONE, | | | | | | | | |
| | , , | | | | | | | |
| | POLYMER WITH AZIRIDINE, GRAFT/CN | | | | | | | |
| (FILE °CAPLUS° ENTERED AT 1 | 5.22.29 ON 04 APR 2002) | | | | | | | |
| L1 1 SEA FILE=REGISTR | Y ABB=ON PLU=ON WATER/CN | | | | | | | |
| L2 1 SEA FILE=REGISTR | Y ABB=ON PLU=ON "SODIUM HYALURONATE"/CN | | | | | | | |
| | ABB=ON PLU=ON (L1 OR WATER OR H2O) AND | | | | | | | |
| | DIUM)(W)HYALURONATE) Y ABB=ON PLU=ON "BUTYLENE GLYCOL"/CN | | | | | | | |
| L8 113 SEA FILE=CAPLUS | ABB=ON PLU=ON L3 AND (L7 OR BUTYLENE | | | | | | | |
| GLYCOL) L10 156 SEA FILE=CAPLUS | ABB=ON PLU=ON (DIMETHICONE OR DI | | | | | | | |
| METHICONE)(S)(PE | G8 OR PEG OR (POLYETHYLENE OR POLY | | | | | | | |
| ETHYLENE) (W) GLYC L11 0 SEA FILE=CAPLUS | OL) ABB=ON PLU=ON L8 AND L10 | | | | | | | |
| | | | | | | | | |
| GILE 'MEDLINE, BIOSIS, EMB JESS-EPIUS, JAPIO' ENTERED | ASE, WPIDS, CONFSCI, SCISEARCH, AT 15:24:38 ON 04 APR 2002) | | | | | | | |
| L12 1 S L11 | | | | | | | | |
| L13 1 S L12 NOT L5 | | | | | | | | |
| L13 ANSWER 1 OF 1 WPIDS COPYRIGHT 2002 DERWENT INFORMATION LTD ACCESSION NUMBER: 2000-256137 [22] WPIDS | | | | | | | | |
| | | | | | | | | |
| DOC. NO. CPI: C2000-0781 | 03 | | | | | | | |
| DOC. NO. CPI: C2000-0781 TITLE: Solid form poorly wat | ulation for improving bioavailability of er-soluble drugs comprises the | | | | | | | |
| DOC. NO. CPI: C2000-0781 TITLE: Solid form poorly wat drug in an | 03 ulation for improving bioavailability of | | | | | | | |
| DOC. NO. CPI: C2000-0781 TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: A96 B05 B0 | ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. | | | | | | | |
| DOC. NO. CPI: C2000-0781 TITLE: Solid form poorly wat drug in an water-solu | ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. | | | | | | | |
| DOC. NO. CPI: TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: INVENTOR(S): PATENT ASSIGNEE(S): COUNTRY COUNT: 24 | ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. | | | | | | | |
| DOC. NO. CPI: TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: INVENTOR(S): PATENT ASSIGNEE(S): (WONJ-N) W | ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. | | | | | | | |
| DOC. NO. CPI: TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: INVENTOR(S): PATENT ASSIGNEE(S): COUNTRY COUNT: 24 | ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. ON JIN BIOPHARMA CO LTD | | | | | | | |
| DOC. NO. CPI: TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: INVENTOR(S): PATENT ASSIGNEE(S): COUNTRY COUNT: PATENT INFORMATION: PATENT NO KIND DATE W WO 2000000179 A1 20000106 (| ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. ON JIN BIOPHARMA CO LTD EEK LA PG 200022)* EN 67 | | | | | | | |
| DOC. NO. CPI: TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: INVENTOR(S): PATENT ASSIGNEE(S): COUNTRY COUNT: PATENT INFORMATION: PATENT NO KIND DATE WO 2000000179 A1 20000106 (RW: AT BE CH CY DE DK ES | ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. ON JIN BIOPHARMA CO LTD EEK LA PG | | | | | | | |
| DOC. NO. CPI: TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: INVENTOR(S): PATENT ASSIGNEE(S): COUNTRY COUNT: PATENT INFORMATION: PATENT NO KIND DATE WO 2000000179 A1 20000106 (RW: AT BE CH CY DE DK ES W: AU CA CN JP US AU 9946556 A 20000117 (| ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. ON JIN BIOPHARMA CO LTD EEK LA PG 200022)* EN 67 FI FR GB GR IE IT LU MC NL PT SE 200026) | | | | | | | |
| DOC. NO. CPI: TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: INVENTOR(S): PATENT ASSIGNEE(S): COUNTRY COUNT: PATENT INFORMATION: PATENT NO KIND DATE WO 2000000179 A1 20000106 (RW: AT BE CH CY DE DK ES W: AU CA CN JP US | ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. ON JIN BIOPHARMA CO LTD EEK LA PG 200022)* EN 67 FI FR GB GR IE IT LU MC NL PT SE 200026) | | | | | | | |
| DOC. NO. CPI: TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: INVENTOR(S): PATENT ASSIGNEE(S): COUNTRY COUNT: PATENT INFORMATION: PATENT NO KIND DATE WO 2000000179 A1 20000106 (RW: AT BE CH CY DE DK ES W: AU CA CN JP US AU 9946556 A 20000117 (| ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. ON JIN BIOPHARMA CO LTD EEK LA PG 200022)* EN 67 FI FR GB GR IE IT LU MC NL PT SE 200026) | | | | | | | |
| DOC. NO. CPI: C2000-0781 TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: A96 B05 B0 INVENTOR(S): LEE, B J PATENT ASSIGNEE(S): (WONJ-N) W COUNTRY COUNT: 24 PATENT INFORMATION: PATENT NO KIND DATE W WO 2000000179 A1 20000106 (RW: AT BE CH CY DE DK ES W: AU CA CN JP US AU 9946556 A 20000117 (KR 2000006503 A 20000125 (| ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. ON JIN BIOPHARMA CO LTD EEK LA PG 200022)* EN 67 FI FR GB GR IE IT LU MC NL PT SE 200026) | | | | | | | |
| DOC. NO. CPI: C2000-0781 TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: A96 B05 B0 INVENTOR(S): LEE, B J PATENT ASSIGNEE(S): (WONJ-N) W COUNTRY COUNT: 24 PATENT INFORMATION: PATENT NO KIND DATE W WO 2000000179 A1 20000106 (RW: AT BE CH CY DE DK ES W: AU CA CN JP US AU 9946556 A 20000117 (KR 2000006503 A 20000125 (APPLICATION DETAILS: PATENT NO KIND | ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. ON JIN BIOPHARMA CO LTD EEK LA PG 200022)* EN 67 FI FR GB GR IE IT LU MC NL PT SE 200026) 200063) APPLICATION DATE | | | | | | | |
| DOC. NO. CPI: C2000-0781 TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: A96 B05 B0 INVENTOR(S): LEE, B J PATENT ASSIGNEE(S): (WONJ-N) W COUNTRY COUNT: 24 PATENT INFORMATION: PATENT NO KIND DATE W WO 2000000179 A1 20000106 (RW: AT BE CH CY DE DK ES W: AU CA CN JP US AU 9946556 A 20000117 (KR 2000006503 A 20000125 (APPLICATION DETAILS: PATENT NO KIND | ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. ON JIN BIOPHARMA CO LTD EEK LA PG 200022)* EN 67 FI FR GB GR IE IT LU MC NL PT SE 200026) 200063) APPLICATION DATE WO 1999-KR341 19990628 AU 1999-46556 19990628 | | | | | | | |
| DOC. NO. CPI: C2000-0781 TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: A96 B05 B0 INVENTOR(S): LEE, B J PATENT ASSIGNEE(S): (WONJ-N) W COUNTRY COUNT: 24 PATENT INFORMATION: PATENT NO KIND DATE W WO 2000000179 A1 20000106 (RW: AT BE CH CY DE DK ES W: AU CA CN JP US AU 9946556 A 20000117 (KR 2000006503 A 20000125 (APPLICATION DETAILS: PATENT NO KIND WO 2000000179 A1 AU 9946556 A KR 2000006503 A | ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. ON JIN BIOPHARMA CO LTD EEK LA PG 200022)* EN 67 FI FR GB GR IE IT LU MC NL PT SE 200026) 200063) APPLICATION DATE | | | | | | | |
| DOC. NO. CPI: C2000-0781 TITLE: Solid form poorly wat drug in an water-solu DERWENT CLASS: A96 B05 B0 INVENTOR(S): LEE, B J PATENT ASSIGNEE(S): (WONJ-N) W COUNTRY COUNT: 24 PATENT INFORMATION: PATENT NO KIND DATE W WO 2000000179 A1 20000106 (RW: AT BE CH CY DE DK ES W: AU CA CN JP US AU 9946556 A 20000117 (KR 2000006503 A 20000125 (APPLICATION DETAILS: PATENT NO KIND | ulation for improving bioavailability of er-soluble drugs comprises the oil and/or fatty acid dispersed in a ble polyol matrix. ON JIN BIOPHARMA CO LTD EEK LA PG 200022)* EN 67 FI FR GB GR IE IT LU MC NL PT SE 200026) 200063) APPLICATION DATE WO 1999-KR341 19990628 AU 1999-46556 19990628 | | | | | | | |

Searcher: Shears 308-4994

PATENT NO

PATENT NO KIND

WO 200000179

A Based on AU 9946556

PRIORITY APPLN. INFO: KR 1999-24437 19990626; KR 1998-24563

2000-256137 [22] 19980627 WPIDS AN

WO 200000179 A UPAB: 20000508 AB

> NOVELTY - A solid dispersed formulation for poorly water -soluble drugs is made by dispersing the drug in an oil and/or fatty acid and mixing the dispersion with a water-soluble polyol matrix and drying the mixture.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for medicines prepared using the novel solid.

USE - The composition is useful for enhancing the bioavailability of poorly water-soluble drugs.

ADVANTAGE - The novel composition provides improved solubility in the gastrointestinal tract giving a great increase in bioavailability. Formulation does not require the use of organic solvents. Dwg.0/5

L14

FILE 'REGISTRY' ENTERED AT 15:26:15 ON 04 APR 2002

2 S (ALLANTOIN OR PANTHENOL)/CN

FILE CAPLUS ENTERED AT 15:26:19 ON 04 APR 2002 -6-8 E8 AND (L14 OR ALLANTOIN OR PANTHENOL) L15

6 S L15 NOT L4 L16

L16 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS 2001:873184 CAPLUS

ACCESSION NUMBER: 136:10924 DOCUMENT NUMBER:

Massage cosmetics containing polymers and oils TITLE:

Hata, Minako INVENTOR(S):

Kosei Co., Ltd., Japan PATENT ASSIGNEE(S):

Jpn. Kokai Tokkyo Koho, 6 pp. SOURCE:

CODEN: JKXXAF

DOCUMENT TYPE: Patent Japanese LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

APPLICATION NO. DATE KIND DATE PATENT NO. -----_____ ----20011204 JP 2000-160489 20000530 JP 2001335460 A2 This invention relates to cosmetic compns. for massaging to provide AΒ skin moisturizing and emollient effects. The compns. comprise (1) acrylamide-2-acrylamido-2-methylpropanesulfonic-acid copolymer (I) 0.03-0.5 %, (2) liq. oils 0.1-50 %, (3) locust bean gum 0.01-0.5 %, (4) xanthan gum 0.01-0.5 %, and (5) nonionic surfactants 0.1-10 %, where the wt. ratio of (3)/(4) being 1/10 - 10/1. A massage cream contained Na hyaluronate aq. soln. 5, 1,3butylene glycol 10, glycerin 5, ethanol 5, locust bean gum 0.1, xanthan gum 0.1, Carbopol 940 0.05, NaOH 0.02, I (40 %) 0.75, D-panthenol 1, seaweed ext. 1, caffeine 0.1, polyoxyethylene sorbitan monooleate 1, sorbitan sesquioleate 1, paraffin oils 10, perfumes 1, and distd. water q.s. to 100

L16 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:371547 CAPLUS

DOCUMENT NUMBER:

134:357402

TITLE:

Cosmetics containing collagens and water

-soluble polymers

INVENTOR(S):

Ozaki, Tadaaki; Matsuda, Norio; Yoshioka, Takashi; Kado, Takayuki; Sugisaki, Mitsuhiko;

Oka, Hiroko

PATENT ASSIGNEE(S):

Iwase Cosfa Co., Ltd., Japan; Nippon Rikagaku

Yakuhin Co., Ltd.

SOURCE:

Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

APPLICATION NO. DATE PATENT NO. KIND DATE _____ _____ ____ -----JP 1999-322995 19991112 20010522 JP 2001139448 A2 This invention relates to transparent cosmetic compns. comprising a AB stable combination of water-sol. collagen type I and water-sol. polymers in a wide range of pH. A moisturizing pack contained collagen type I 10, montmorillonite 3, Na CMC 0.2, hydroxyethyl cellulose 0.1, polyoxyethylene sorbitan monooleate 0.5, 1,3-butylene glycol 6, citric acid 0.2, talc 20, kaolin 7, titania 5, Na hyaluronate 0.005, allantoin 0.1, Na citrate 1.5, lavender ext. 0.1,

methylparaben q.s., and distd. water to 100 %.

IT 9067-32-7, Sodium hyaluronate

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(cosmetics contg. collagens and water-sol. polymers)

L16 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

2000:14983 CAPLUS

DOCUMENT NUMBER:

132:83650

TITLE:

Solid dispersed preparation of poorly

water-soluble drug containing oil, fatty

acid or mixtures thereof

INVENTOR(S):

Lee, Beom Jin

PATENT ASSIGNEE(S):

Won Jin Biopharma Co., Ltd., S. Korea

SOURCE:

PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2000000179 A1 20000106 WO 1999-KR341 19990628

W: AU, CA, CN, JP, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,

NL, PT, SE

KR 2000006503 A 20000125 KR 1999-24437 19990626 AU 9946556 A1 20000117 AU 1999-46556 19990628 PRIORITY APPLN. INFO.: KR 1998-24563 A 19980627

KR 1999-24437 A 19990626 WO 1999-KR341 W 19990628

AΒ Disclosed is a solid dispersed prepn. for poorly water -sol. drugs, which is prepd. by dissolving or dispersing the poorly water-sol. drugs in an oil, a fatty acid or a mixt. thereof, mixing the soln. or dispersion in a water-sol. polyol matrix and drying the mixt. The solid dispersed prepn. can be formulated into a power formulation or a granule formulation. The solid dispersed prepn. is improved in the soly. of poorly water-sol. drugs in the gastro-intestinal tract, resulting in a great increase in the bioavailability of the drugs. In addn., the solid dispersed prepn. gives the pharmaceutical solns. to the problems that the conventional semi-solid or liq. prepns. possess, enabling medicinally effective, poorly water-sol. compds. to be formulated, molded and processed, quickly and in an economically favorable manner without use of any org. solvent. Examples are given for emulsions contg. mixts. of waxes, oils, and aq. phase.

IT 81-13-0, Panthenol 107-88-0,
 1,3-Butanediol 9067-32-7, Sodium

hyaluronate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (solid dispersed prepn. of poorly water-sol. drug

contg. oils and fatty acid or mixts.)

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN

THE RE FORMAT

L16 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1998:527045 CAPLUS

DOCUMENT NUMBER:

BER: 129:166083

TITLE:

Sunscreen compositions containing a UV-A

dibenzoylmethane derivative and an alkyl.

salicylate stabilizer/solubilizer Bonda, Craig A.; Hopper, Steven P.

PATENT ASSIGNEE(S):

The C. P. Hall Company, USA

SOURCE:

U.S., 8 pp. Cont.-in-part of U.S. Ser. No.

752,585.

CODEN: USXXAM

DOCUMENT TYPE:

Patent English

LANGUAGE:

INVENTOR(S):

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------|------|----------|-------------------|----------|
| US 5788954 | Α | 19980804 | US 1997-967121 | 19971112 |
| | | | | |
| US 5783173 | Α | 19980721 | US 1996-752585 | 19961121 |
| AU 9745324 | A1 | 19980528 | AU 1997-45324 | 19971120 |
| AU 728369 | B2 | 20010111 | | |
| US 5849273 | A | 19981215 | US 1997-984765 | 19971204 |
| US 6350894 | B1 | 20020226 | US 2000-523336 | 20000310 |
| PRIORITY APPLN. INFO. | : | | US 1996-752585 A2 | 19961121 |
| | | | US 1997-967121 A2 | 19971112 |
| | | | US 1998-7503 A1 | 19980115 |

OTHER SOURCE(S): MARPAT 129:166083

AB A sunscreen compn. contg. a UV-A dibenzoylmethane deriv., such as 4-(1,1-dimethylethyl)-4'-methoxydibenzoylmethane (PARSOL 1789), and

an alkyl salicylate stabilizer/solubilizer for the dibenzoylmethane deriv. is disclosed. A sunscreen contained octyl methoxycinnamate 1-10, butyloctyl salicylate 1-15, hexyldecyl benzoate & butyloctyl benzoate 0-10, avobenzone 0.5-5, polyvinylpyrrolidone eicosene copolymer 0-2, dimethicone copolyol 0-2, tocopheryl acetate 0-2, retinyl palmitate 0-2, bisabolol 0-2, sorbitan oleate 0-5, acrylate/C10-30 alkyl acrylate crosspolymer 0.1-5, silica 0-5, water 50-80, xanthan gum 0-2, cetyl hydroxyethyl cellulose 0-2, glycerin 0-10, butylene glycol 0-5, phenylethanol, methylparaben, ethylparaben, propylparaben, and butylparaben 0-5, panthenol 0-5, triethanolamine 0-1, preservative 0-1, green tea ext. 0-2, biol. ext. selected 0-5 from horsetail ext., myrrh ext., sunflower seed ext., wheat germ ext., and mixts. thereof 0-5, sodium hyaluronate 0-1, and polyacrylamide 0-2%.

IT 81-13-0, Panthenol

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(sunscreen compns. contg. UV-A dibenzoylmethane deriv. and alkyl salicylate stabilizer/solubilizer)

L16 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1992:180944 CAPLUS

ACCESSION NUMBER: DOCUMENT NUMBER:

116:180944

TITLE:

Topical preparations containing resorcin

glycosides

INVENTOR(S):

Hamazaki, Taihei; Matsugami, Michio; Takenochi,

Masanori; Utsugi, Koji; Nakano, Hiroyuki

PATENT ASSIGNEE(S):

Pola Chemical Industries, Inc., Japan Jpn. Kokai Tokkyo Koho, 10 pp.

SOURCE:

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------------|----------|----------------------|-----------------|----------|
| JP 04001116 JP 2860902 | A2 B2 | 19920106 19990224 | JP 1990-99919 | 19900416 |

OTHER SOURCE(S): MARPAT 116:180944

Topical prepns., which inhibit melanin formation, contain m-ROC6H4OH (R = pentosyl, hexosyl, amino sugar residue, uronic acid residue, etc.). Vaseline 5.0, liq. paraffin 15.0, cetanol 5.0, glycerin monostearate 2.0, polyoxyethylene sorbitan monostearate 2.0, Bu p-hydroxybenzoate 0.2, perfumes 0.2, 1,3-butylene glycol 10.0, di-Na edetate 0.1, H2O 57.5, and m-hydroxyphenyl-.beta.-D-glycoside (I) 3.0 wt. parts were mixed to give a skin cream, which showed skin-lightening effect and wound healing promotion. I is nonirritating.

IT 97-59-6, Allantoin 9067-32-7,

Sodium hyaluronate

RL: BIOL (Biological study)

(skin-lightening cosmetics contg. resorcin glycosides and)

L16 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1988:636757 CAPLUS

DOCUMENT NUMBER:

109:236757

TITLE:

p-Hydroxybenzoate ester-free cosmetics

containing 1,3-butylene glycol , surfactants, and organic acids

INVENTOR(S):

Fujii, Masashi; Ito, Minoru

PATENT ASSIGNEE(S):

Noevir Co., Ltd., Japan

SOURCE:

AB

IT

Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE ____ -----

APPLICATION NO. DATE _____

JP 63188610

A2 19880804 JP 1987-21540 19870130

The title cosmetics, which are not irritating to the skin and have

good bactericidal activities, contain 3-20% 1,3-butylene glycol (I) and .gtoreq.1 compd. chosen from surfactants

(inorg.-org. balance 1.20-2.00) and org. acids. A cosmetic comprising glycerin 3.00, I 2.00, allantoin 0.10, Na

pyrrolidonecarboxylate 0.10, Na hyaluronate

0.10, lactic acid (II) 0.10, flavoring material 0.10, and 94.45%

H2O showed no irritation to the skin and complete control for Escherichia coli, Pseudomonas aeruginosa, P. cepacia,

Staphylococcus aureus, but a control contg. Me p-hydroxybenzoate instead of II produced skin irritation.

107-88-0, 1,3-Butylene glycol

RL: BIOL (Biological study)

(cosmetics contg. surfactant and org. acid and)

(FILE OMEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLOS, JAPIO' ENTERED AT 15:27:17 ON 04 APR 2002)

L17 1 S L15

0 S L17 NOT (L5 OR L12) L18

=> fil hom

FILE 'HOME' ENTERED AT 15:34:16 ON 04 APR 2002

Shears 308-4994 Searcher: